var title_f21_19_21808="Diagnosis of CAPS without history of APS or aPL";
var content_f21_19_21808=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F66464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F66464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 651px\">",
"   <div class=\"ttl\">",
"    Diagnosis of catastrophic antiphospholipid syndrome (APS): Patients lacking history of APS or persistent positive antiphospholipid antibody",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 631px; height: 613px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Catastrophic antiphospholipid syndrome (APS) diagnosis in patients without history of APS or persistent antiphospholipid antibody (aPL)���������positivity.",
"    <div class=\"footnotes\">",
"     * Our recommendation for the definition of \"positive aPL\" is: lupus anticoagulant (LA) test positive based on the guidelines of International Society of Haemostasis; anticardiolipin antibody (aCL) IgG/M &ge;40 U, and/or anti���������&beta;2���������glycoprotein���������l antibody (a&beta;2GPI) IgG/M &ge;40 U. Caution and further assessment(s) are required if: a) LA test is performed in anticoagulated patients; b) aCL or a&beta;2GPI IgG/M titers are in the range of 20-39 U; and/or c) aCL or a&beta;2GPI IgA is the only positive aPL ELISA test.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      \"Positive aPL\" twice 12 weeks apart (of note, the original Sapporo APS classification criteria required two positive aPL tests 6 weeks apart, which has been changed to 12 weeks as part of the updated Sapporo APS classification criteria).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     From: Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev 2010; 10:74. Illustration used with the permission from Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_19_21808=[""].join("\n");
var outline_f21_19_21808=null;
var title_f21_19_21809="Sclerocornea";
var content_f21_19_21809=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sclerocornea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Four-month-old with sclerocornea. Both corneas appear opaque with an undetectable limbus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_19_21809=[""].join("\n");
var outline_f21_19_21809=null;
var title_f21_19_21810="Serous cystadenoma";
var content_f21_19_21810=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreatic serous cystadenoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT showing a serous cystadenoma of the pancreas. Note central calcification of stellate scar (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin McGrath, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_19_21810=[""].join("\n");
var outline_f21_19_21810=null;
var title_f21_19_21811="Methoxsalen (topical): Drug information";
var content_f21_19_21811=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methoxsalen (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/5/2132?source=see_link\">",
"    see \"Methoxsalen (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8770767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Oxsoralen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8770768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Oxsoralen&reg; Lotion",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8770804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Psoralen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8770897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Refer to treatment protocols for UVA exposure guidelines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vitiligo:",
"     </b>",
"     Topical: Lotion is applied by healthcare provider prior to UVA light exposure, usually no more than once weekly; frequency is determined by erythema response",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8770896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Vitiligo:",
"     </b>",
"     Topical: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8770898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8770931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oxsoralen&reg;: 1% (29.57 mL) [contains ethanol 71%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8770770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8770918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hands and fingers of person applying the lotion should be protected to prevent possible photosensitization and/or burns.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8770849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Repigmentation of idiopathic vitiligo",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8770858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Blistering, burn, erythema, irritation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8770854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methoxsalen (psoralens) or any component of the formulation; diseases associated with photosensitivity (eg, albinism, lupus erythematosus, porphyria [cutanea tarda, erythropoietic and variegate], xeroderma pigmentosum); invasive skin cancer; melanoma or history of melanoma; children &lt;12 years of age",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8770855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Burns: Serious burns may occur from ultraviolet radiation or sunlight (even if exposed through glass) if recommended exposure schedule is exceeded and/or protective clothing/sunscreen is not used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cataracts: Methoxsalen concentrates in the lens; eyes should be shielded from direct and indirect sunlight for 24 hours to prevent possible formation of cataracts. The risk associated with topical therapy is likely to be lower due to reduced systemic exposure to methoxsalen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Avoid sun (including sun lamp) exposure for 8 hours after methoxsalen exposure. Protective clothing, eyewear, and sunscreen (do not apply sunscreen to psoriatic areas) should be used for several days after combined methoxsalen/UVA therapy. Do not use in sunburned patients until they have fully recovered; pre-existing sunburn may obscure evaluation of response; advise patients to avoid sunbathing for 24 hours prior to treatment and for several days after treatment. Use extreme caution in patients who have significant exposure to the sun through their occupations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin cancer: Systemic therapy increases risk of skin cancer (basal cell, melanoma and squamous cell); has not been reported with topical treatment; use caution with fair skin or prior exposure to coal tar/UV treatment, ionizing radiation, or arsenic.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Basal cell carcinoma: Use with caution in patients with multiple basal cell carcinomas or a history of basal cell carcinoma; observe closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitizing agents: Use caution with other (systemic or topical) photosensitizing drugs (eg, thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides, anthralin, coal tar preparations).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use is contraindicated in children &lt;12 years of age; safety and efficacy have not been established. The long-term effects of treatment (including potential cataract formation, skin cancer development, and premature skin aging) are unknown in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician: Should be administered under the supervision of an experienced physician with special competence in the diagnosis and treatment of dermatologic diseases.  Product should",
"     <b>",
"      not",
"     </b>",
"     be dispensed to the patient.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8770862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8770850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8770851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted with topical methoxsalen. The extent of absorption is not known. Avoid use in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8770853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Oxsoralen External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (29.57 mL): $596.26",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13276705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Geroxalen (NL);",
"     </li>",
"     <li>",
"      Lukodermine (PK);",
"     </li>",
"     <li>",
"      Meladinina (CR, DO, GT, NI, PA, SV);",
"     </li>",
"     <li>",
"      Meladinine (CL, FR);",
"     </li>",
"     <li>",
"      Melanocyl (IN);",
"     </li>",
"     <li>",
"      Melaoline (GR);",
"     </li>",
"     <li>",
"      Mopsalem (CO);",
"     </li>",
"     <li>",
"      Oxsoralen (AE, AT, BH, CH, CY, EG, HK, HN, IQ, IR, JO, JP, KW, LB, LY, NL, OM, PK, PL, QA, SA, SG, SY, YE);",
"     </li>",
"     <li>",
"      Oxsoralen Lotion (ID);",
"     </li>",
"     <li>",
"      Oxsoralen Ultra (SG);",
"     </li>",
"     <li>",
"      Uvadex (CZ, FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8770867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bonds covalently to pyrimidine bases in DNA, inhibits the synthesis of DNA, and suppresses cell division. The augmented sunburn reaction involves excitation of the methoxsalen molecule by radiation in the long-wave ultraviolet light (UVA), resulting in transference of energy to the methoxsalen molecule producing an excited state (&ldquo;triplet electronic state&rdquo;). The molecule, in this &ldquo;triplet state,&rdquo; then reacts with cutaneous DNA. Causes photosensitization which leads to cell inquiry and an inflammatory reaction. The erythematous reaction is followed over days to weeks by repair which manifests as higher melanization of the epidermis and thickening with the stratum corneum. Frequency is regulated by the erythema by healthcare provider response.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9578 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-FC54B750F8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_19_21811=[""].join("\n");
var outline_f21_19_21811=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770767\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770768\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770804\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770897\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770896\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770898\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770931\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770770\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770918\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770849\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770858\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770854\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770855\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299691\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770862\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770850\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770851\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770853\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322287\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276705\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770867\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9578\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9578|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/59/37813?source=related_link\">",
"      Methoxsalen (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/41/24212?source=related_link\">",
"      Methoxsalen (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/5/2132?source=related_link\">",
"      Methoxsalen (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_19_21812="Para-aminosalicylic acid: Patient drug information";
var content_f21_19_21812=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Para-aminosalicylic acid: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15141?source=see_link\">",
"     see \"Para-aminosalicylic acid: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F133540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Paser&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat TB (tuberculosis).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to aminosalicylic acid or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697346",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have ulcer disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698109",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Granule shell in the stool.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695459",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix with apple, orange, or tomato juice and drink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Granules may be sprinkled on applesauce or yogurt. Do not chew.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use if packet is swollen or granules are dark brown or purple.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11460 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.97.94.19-BA627EFD15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_19_21812=[""].join("\n");
var outline_f21_19_21812=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133540\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025509\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025508\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025513\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025514\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025516\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025511\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025512\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025517\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025518\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15141?source=related_link\">",
"      Para-aminosalicylic acid: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_19_21813="Koenen tumor";
var content_f21_19_21813=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Periungual fibroma in tuberous sclerosis (Koenen tumor)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 391px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Dermatology Online Atlas, www.dermis.net. Copyright &copy; 2012. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_19_21813=[""].join("\n");
var outline_f21_19_21813=null;
var title_f21_19_21814="Globus sensation";
var content_f21_19_21814=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Globus sensation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/19/21814/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/19/21814/contributors\">",
"     Kristen Robson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/19/21814/contributors\">",
"     Anthony J Lembo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/19/21814/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/19/21814/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/19/21814/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/19/21814/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/19/21814/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H480081804\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Globus sensation (which has also been referred to as globus pharyngeus and globus hystericus) is common in the general population. This topic will review the definition, epidemiology, etiology, clinical manifestations and the evaluation and treatment of patients with globus sensation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H480081797\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Globus sensation has been defined using the following criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The persistent or intermittent nonpainful sensation of a lump or foreign body in the throat",
"     </li>",
"     <li>",
"      Occurrence of the sensation between meals",
"     </li>",
"     <li>",
"      Absence of dysphagia and odynophagia",
"     </li>",
"     <li>",
"      Absence of evidence that gastroesophageal reflux is the cause of symptoms",
"     </li>",
"     <li>",
"      Absence of histopathology-based esophageal motility disorders",
"     </li>",
"     <li>",
"      Criteria fulfilled for the last three months with symptom onset at least six months before diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Globus sensation (which has also been referred to as globus pharyngeus and globus hystericus) is common in the general population as illustrated in a study in which 45 percent of 147 healthy volunteers had experienced it at least once [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/2\">",
"     2",
"    </a>",
"    ]. The sensation usually occurred during an emotional event and was more common in women (53 versus 35 percent).",
"   </p>",
"   <p>",
"    Some patients have recurrent or persistent globus that is the primary reason they seek medical care. In one report, for example, globus sensation was the primary reason for consultation in 4 percent of 4330 consecutive new patients seen at a general otolaryngology clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/3\">",
"     3",
"    </a>",
"    ]. Globus was three times more common in women than in men who were under the age of 50, while there was no difference in prevalence between men and women over the age of 50. In another series involving 88 patients referred to a psychosomatic center because of globus, the median age was 43 (range 22 to 71), and the median duration of symptoms was two years (range 1 month to 36 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of globus is unknown but it has been associated with multiple disorders (",
"    <a class=\"graphic graphic_table graphicRef59444 \" href=\"UTD.htm?11/18/11563\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/4\">",
"     4",
"    </a>",
"    ]. Although the data are limited, the areas that have received the greatest amount of attention have been gastroesophageal reflux disease (GERD), abnormalities of the upper esophageal sphincter (UES), psychologic and psychiatric disorders, and stress. In addition, in one series, achalasia was diagnosed in 27 percent of 88 patients (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Gastroesophageal reflux disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between globus sensation and GERD has been suggested based upon clinical experience and a number of small studies, most of which have been uncontrolled [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In a small controlled study, 24-hour esophageal pH studies and endoscopic and manometric findings were compared between 26 patients with globus and 20 patients with nonulcer dyspepsia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients with globus were significantly more likely than controls to have abnormal pH studies (31 versus 5 percent), while manometric studies were not different. An association between globus and symptoms of reflux was also suggested in a population-based study involving 2200 citizens of Olmsted County, Minnesota [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/7\">",
"     7",
"    </a>",
"    ]. Esophageal impedance-pH studies appear to increase the yield in identifying patients whose reflux (acid and non-acid) correlate with globus sensation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/8\">",
"     8",
"    </a>",
"    ]. Nonerosive reflux was found to be a greater independent risk factor for developing globus (odds ratio 12.1) than an inlet patch (odds ratio 2.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26247?source=see_link\">",
"     \"Esophageal multichannel intraluminal impedance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, discordant data have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. In two studies that included a total of 92 patients, for example, the prevalence of an abnormal pH study among patients with globus was similar to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Further support for an argument against an association with GERD is the observation that patients with globus infrequently have a positive Bernstein test (in which the infusion of dilute hydrochloric acid is used to determine whether symptoms are acid related) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another theory linking reflux with globus is the speculation that globus may be related to upper esophageal sphincter contraction induced by acid exposure in the distal esophagus. However, in one report, acid infusion into the esophagus did not affect UES pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Considering these data together, it appears unlikely that GERD has a major role in the pathogenesis of globus. Nevertheless, it is possible that globus may be an atypical manifestation of GERD in a subset of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19946665\">",
"    <span class=\"h2\">",
"     Visceral hypersensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity to balloon distention is a common feature in patients with functional bowel disorders. In one study, nine patients with globus were found to be hypersensitive to balloon distention but not electrical stimulation of the esophagus compared to healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, the majority of patients with globus and none of the healthy controls referred the sensation during balloon distention to the suprasternal notch, suggesting that patients with globus may have aberrant central processing of esophageal sensations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Upper esophageal sphincter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal upper esophageal sphincter function has also been hypothesized to be a cause of globus sensation. This was illustrated in a report in which a hypertensive UES was found much more frequently among patients who reported globus sensation than controls (28 versus 3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/11\">",
"     11",
"    </a>",
"    ]. Another report found that respiration-related changes in resting UES pressure were significantly amplified in patients with globus compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies, however, have not demonstrated any difference in UES resting pressure between controls and those with globus sensation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. One limitation is that these studies used manometric techniques less accurate than the circumferential solid state transducer used in the study discussed above [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A significant increase in the UES pressure after wet swallows has also been described in patients with globus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/18\">",
"     18",
"    </a>",
"    ]. The clinical significance of this finding is questionable since most patients with globus sensation do not complain of difficulty swallowing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Psychologic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with globus score higher on self-reported measures of neuroticism, introversion, anxiety, and depression than controls [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. Psychologic disturbances (such as anxiety and somatic concern) are more common in women with globus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. However, so called \"hysterical\" personality traits do not appear to be more common in patients with globus; thus, the term \"globus hystericus\" is a misnomer and should not be used [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/21,23\">",
"     21,23",
"    </a>",
"    ]. Furthermore, despite these associations, not all patients with globus have psychologic or psychiatric abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute stress has been hypothesized to influence the development of globus, possibly by affecting UES pressure. However, this theory was disproven in a controlled trial in which UES pressure was no different between 7 patients with globus and 13 controls after provocation with stressful stimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/17\">",
"     17",
"    </a>",
"    ]. Furthermore, symptoms were not elicited by stress in patients with a history of globus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, a variety of conditions have been associated with globus, the clinical features of which may accompany the globus sensation (",
"    <a class=\"graphic graphic_table graphicRef59444 \" href=\"UTD.htm?11/18/11563\">",
"     table 1",
"    </a>",
"    ). In other patients, the sensation occurs in isolation.",
"   </p>",
"   <p>",
"    In a series of 88 patients referred to a psychosomatic center because of globus, globus was described as intermittent in 70 percent, with the remainder experiencing persistent symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/4\">",
"     4",
"    </a>",
"    ]. Conditions exacerbating or precipitating symptoms included, most commonly, states of fear, tension, anger, or mental stress (in approximately 30 percent of patients). A variety of other triggers were described including a response to eating or to certain head or body positions. The sensation was improved in approximately 36 percent of patients during periods of relaxation or distraction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;No consensus has been established for the optimal evaluation of patients with globus. The benefits of evaluation have to be weighed against the risk, expense, and the low probability of finding an abnormality that will affect treatment decisions, particularly in patients in whom the sensation has been present for many years. Nevertheless, some patients may become particularly bothered by the globus and, on occasion, it becomes an obsessive focus. Thus, in most patients with recurrent or persistent symptoms, a diagnostic evaluation is appropriate.",
"   </p>",
"   <p>",
"    The results of the study involving 88 patients with globus described above illustrate the heterogeneity of findings that may be encountered in patients with globus who undergo intensive evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition to standard laboratory tests and physical examination, patients were asked to complete several psychological batteries, and other testing including otolaryngologic examination, videofluoroscopic and manometric evaluations of pharyngoesophageal function, upper endoscopy, and assessment of gastric emptying. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      15 patients (17 percent) had normal pharyngoesophageal function. Many of these patients had some other abnormality including chronic tonsillitis or pharyngitis, thyroid adenoma, cervical spondylosis, dry oropharyngeal mucosa and chronic bronchitis. However, the association of some of these findings and the globus sensation was unclear.",
"     </li>",
"     <li>",
"      73 patients (83 percent) had pharyngoesophageal abnormalities, the most common of which were achalasia (24 patients) and nonspecific esophageal motility disorders (30 patients). Other abnormalities included gastroesophageal reflux disease (13 patients) and, infrequently, abnormal UES function, diffuse esophageal spasm, and nutcracker esophagus.",
"     </li>",
"     <li>",
"      Psychometric testing revealed no more depression or anxiety than that observed in general medical patients without globus, although 37 of 58 (64 percent) who underwent formal psychiatric interviews met formal criteria for psychiatric disorders. However, the high prevalence of psychiatric diagnoses may reflect referral bias since patients were seen in a clinic specializing in psychosomatic and psychophysiologic disorders.",
"     </li>",
"     <li>",
"      The most striking finding of this study was the detection of achalasia in a high proportion of patients, the majority of whom had no other complaints raising suspicion for the disease. A possible explanation of the globus sensation in these patients is the persistence of food and saliva in the esophagus between meals. After the diagnosis was made, the majority of patients reported at least one symptom compatible with achalasia that had not been initially considered severe enough for them to volunteer the information. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=see_link\">",
"       \"Clinical manifestations and diagnosis of achalasia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Follow-up of the 88 patients ranging from 3 to 59 months demonstrated that the sensation vanished spontaneously in 13 percent of those who had received nonspecific or no treatment, improved in an additional 25 percent, and was unchanged in 32 percent. The benefit of specific treatments for the disorders discussed above was also variable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other reports have suggested variable benefits from specific diagnostic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. In one series, no serious abnormalities were detected in 2011 patients who underwent a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/25\">",
"     25",
"    </a>",
"    ]. In another series of 451 patients, the combination of fiber optic nasoendoscopy plus barium swallow identified most serious pathology (five aerodigestive tract malignancies) except one patient who had a distal peptic stricture [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The above evaluation may not be successful for directing specific therapy, and symptoms persist in many patients who seek help for globus. In patients with continued troubling symptoms, additional work-up may include videofluoroscopic or manometric assessment of esophageal function. Ambulatory pH monitoring may be helpful if reflux is suspected. As an alternative, many clinicians rely upon an empiric trial of acid suppression. Specific testing for occult thyroid enlargement has been recommended by some investigators [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/28\">",
"     28",
"    </a>",
"    ]. Thyroidectomy for a goiter improved globus symptoms in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, symptoms persist in many patients despite a thorough diagnostic evaluation. Treatment in such patients is generally supportive. Although psychologic characteristics may influence the discomfort experienced by patients, they probably do not affect the clinical course [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/4\">",
"     4",
"    </a>",
"    ]. As a result, psychiatric referral is unlikely to cure the problem. However, psychiatric consultation may assist patients to cope with the sensation.",
"   </p>",
"   <p>",
"    In addition, pharmacologic therapy for depression using the tricyclic antidepressant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    has been beneficial for some patients who had concomitant psychiatric disorders such as panic, somatization, major depression, and agoraphobia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Other pharmacological therapies including H2 blockers, proton pump inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"     sucralfate",
"    </a>",
"    , antacids, and benzodiazepines are of unproven benefit, but may have a role in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/4,32,33\">",
"     4,32,33",
"    </a>",
"    ]. Approximately one-third of patients experienced partial relief with a PPI in an observational study of 64 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relaxation therapy may have a role in treating patients with refractory globus symptoms. In a case series, 10 women with globus who were unresponsive to reflux treatment and with normal",
"    <span class=\"nowrap\">",
"     esophageal/laryngeal",
"    </span>",
"    imaging underwent a seven-session clinical protocol with hypnotically-assisted relaxation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/34\">",
"     34",
"    </a>",
"    ]. Following treatment, 9 out of the 10 patients reported a reduction in globus symptomatology.",
"   </p>",
"   <p>",
"    An initial observational study followed by a small controlled sham trial from the same group suggested that ablation of gastric inlet patches by argon plasma coagulation can improve chronic globus symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21814/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Additional studies are needed to confirm these findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/18/2346?source=see_link\">",
"     \"Benign lesions of the esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Globus sensation is defined as the persistent or intermittent nonpainful sensation of a lump or foreign body in the throat with occurrence of the sensation between meals. Globus is characterized by the absence of all of the following including dysphagia and odynophagia, evidence that gastroesophageal reflux is the cause of symptoms and the histopathology-based esophageal motility disorder. These criteria must be fulfilled for the last three months with symptom onset at least six months before diagnosis. (See",
"      <a class=\"local\" href=\"#H480081797\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Globus sensation is common in the general population. The etiology is unknown but it has been associated with multiple disorders (",
"      <a class=\"graphic graphic_table graphicRef59444 \" href=\"UTD.htm?11/18/11563\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the following as a reasonable approach to patients who present with globus as a primary complaint. All patients should undergo a careful history with a particular focus on identifying signs or symptoms of an esophageal motility disorder, especially achalasia. &nbsp;A complete physical and otolaryngological examination (usually requiring referral) should be performed. In addition, we usually perform a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      swallow with a solid bolus (such as bread or a barium tablet) to exclude a mechanical problem and to look for an obvious, underlying motility disorder. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=see_link\">",
"       \"Clinical manifestations and diagnosis of achalasia\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In patients in whom the above evaluation is unrevealing, further diagnostic testing can be performed based upon the severity and duration of symptoms bearing in mind that the condition will be unexplained in the majority of patients. On the other hand, appropriate endoscopic or barium studies should be obtained in patients in whom globus is new (particularly in older patients), in those in whom it has changed, or those with alarm symptoms (such as weight loss, anemia, dysphagia, or odynophagia.)",
"      <br/>",
"      <br/>",
"      In patients with continued troubling symptoms, additional work-up may include videofluoroscopic or manometric assessment of esophageal function. Ambulatory pH monitoring may be helpful if reflux is suspected. As an alternative, many clinicians rely upon an empiric trial of acid suppression. Specific testing for occult thyroid enlargement has been recommended by some investigators.",
"     </li>",
"     <li>",
"      Globus sensation may persist despite a thorough evaluation. We suggest empiric trials of therapy in such patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Psychiatric consultation may assist patients to cope with the sensation. Pharmacologic therapy for depression using the tricyclic antidepressant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"       imipramine",
"      </a>",
"      has been beneficial for some patients who had concomitant psychiatric disorders such as panic, somatization, major depression, and agoraphobia. Other pharmacological therapies including H2 blockers, proton pump inhibitors,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"       sucralfate",
"      </a>",
"      , antacids, and benzodiazepines are of unproven benefit, but may have a role in selected patients. Relaxation therapy could be considered although its effects are likely to be nonspecific. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/1\">",
"      Galmiche JP, Clouse RE, B&aacute;lint A, et al. Functional esophageal disorders. Gastroenterology 2006; 130:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/2\">",
"      Thompson WG, Heaton KW. Heartburn and globus in apparently healthy people. Can Med Assoc J 1982; 126:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/3\">",
"      Moloy PJ, Charter R. The globus symptom. Incidence, therapeutic response, and age and sex relationships. Arch Otolaryngol 1982; 108:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/4\">",
"      Moser G, Wenzel-Abatzi TA, Stelzeneder M, et al. Globus sensation: pharyngoesophageal function, psychometric and psychiatric findings, and follow-up in 88 patients. Arch Intern Med 1998; 158:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/5\">",
"      Woo P, Noordzij P, Ross JA. Association of esophageal reflux and globus symptom: comparison of laryngoscopy and 24-hour pH manometry. Otolaryngol Head Neck Surg 1996; 115:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/6\">",
"      Hill J, Stuart RC, Fung HK, et al. Gastroesophageal reflux, motility disorders, and psychological profiles in the etiology of globus pharyngis. Laryngoscope 1997; 107:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/7\">",
"      Locke GR 3rd, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/8\">",
"      Anandasabapathy S, Jaffin BW. Multichannel intraluminal impedance in the evaluation of patients with persistent globus on proton pump inhibitor therapy. Ann Otol Rhinol Laryngol 2006; 115:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/9\">",
"      Hori K, Kim Y, Sakurai J, et al. Non-erosive reflux disease rather than cervical inlet patch involves globus. J Gastroenterol 2010; 45:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/10\">",
"      Wilson JA, Heading RC, Maran AG, et al. Globus sensation is not due to gastro-oesophageal reflux. Clin Otolaryngol Allied Sci 1987; 12:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/11\">",
"      Corso MJ, Pursnani KG, Mohiuddin MA, et al. Globus sensation is associated with hypertensive upper esophageal sphincter but not with gastroesophageal reflux. Dig Dis Sci 1998; 43:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/12\">",
"      F&auml;rkkil&auml; MA, Ertama L, Katila H, et al. Globus pharyngis, commonly associated with esophageal motility disorders. Am J Gastroenterol 1994; 89:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/13\">",
"      Vakil NB, Kahrilas PJ, Dodds WJ, Vanagunas A. Absence of an upper esophageal sphincter response to acid reflux. Am J Gastroenterol 1989; 84:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/14\">",
"      Chen CL, Szczesniak MM, Cook IJ. Evidence for oesophageal visceral hypersensitivity and aberrant symptom referral in patients with globus. Neurogastroenterol Motil 2009; 21:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/15\">",
"      Kwiatek MA, Mirza F, Kahrilas PJ, Pandolfino JE. Hyperdynamic upper esophageal sphincter pressure: a manometric observation in patients reporting globus sensation. Am J Gastroenterol 2009; 104:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/16\">",
"      Caldarelli DD, Andrews AH Jr, Derbyshire AJ. Esophageal motility studies in globus sensation. Ann Otol Rhinol Laryngol 1970; 79:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/17\">",
"      Cook IJ, Dent J, Collins SM. Upper esophageal sphincter tone and reactivity to stress in patients with a history of globus sensation. Dig Dis Sci 1989; 34:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/18\">",
"      Wilson JA, Pryde A, Piris J, et al. Pharyngoesophageal dysmotility in globus sensation. Arch Otolaryngol Head Neck Surg 1989; 115:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/19\">",
"      Deary IJ, Smart A, Wilson JA. Depression and 'hassles' in globus pharyngis. Br J Psychiatry 1992; 161:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/20\">",
"      Wilson JA, Deary IJ, Maran AG. Is globus hystericus? Br J Psychiatry 1988; 153:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/21\">",
"      Deary IJ, Wilson JA, Mitchell L, Marshall T. Covert psychiatric disturbance in patients with globus pharyngis. Br J Med Psychol 1989; 62 ( Pt 4):381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/22\">",
"      Wilson JA, Deary IJ, Mardon SL. Globus (letter). Lancet 1989; 1:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/23\">",
"      Bradley PJ, Narula A. Clinical aspects of pseudodysphagia. J Laryngol Otol 1987; 101:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/24\">",
"      Takwoingi YM, Kale US, Morgan DW. Rigid endoscopy in globus pharyngeus: how valuable is it? J Laryngol Otol 2006; 120:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/25\">",
"      Hajioff D, Lowe D. The diagnostic value of barium swallow in globus syndrome. Int J Clin Pract 2004; 58:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/26\">",
"      Harar RP, Kumar S, Saeed MA, Gatland DJ. Management of globus pharyngeus: review of 699 cases. J Laryngol Otol 2004; 118:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/27\">",
"      Caylakli F, Yavuz H, Erkan AN, et al. Evaluation of patients with globus pharyngeus with barium swallow pharyngoesophagography. Laryngoscope 2006; 116:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/28\">",
"      Marshall JN, McGann G, Cook JA, Taub N. A prospective controlled study of high-resolution thyroid ultrasound in patients with globus pharyngeus. Clin Otolaryngol Allied Sci 1996; 21:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/29\">",
"      Maung KH, Hayworth D, Nix PA, et al. Thyroidectomy does not cause globus pattern symptoms. J Laryngol Otol 2005; 119:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/30\">",
"      Cybulska EM. Globus hystericus--a somatic symptom of depression? The role of electroconvulsive therapy and antidepressants. Psychosom Med 1997; 59:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/31\">",
"      Brown SR, Schwartz JM, Summergrad P, Jenike MA. Globus hystericus syndrome responsive to antidepressants. Am J Psychiatry 1986; 143:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/32\">",
"      Cybulska EM. Globus hystericus or depressivus? Hosp Med 1998; 59:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/33\">",
"      Sinn DH, Kim JH, Kim S, et al. Response rate and predictors of response in a short-term empirical trial of high-dose rabeprazole in patients with globus. Aliment Pharmacol Ther 2008; 27:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/34\">",
"      Kiebles JL, Kwiatek MA, Pandolfino JE, et al. Do patients with globus sensation respond to hypnotically assisted relaxation therapy? A case series report. Dis Esophagus 2010; 23:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/35\">",
"      Meining A, Bajbouj M, Preeg M, et al. Argon plasma ablation of gastric inlet patches in the cervical esophagus may alleviate globus sensation: a pilot trial. Endoscopy 2006; 38:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21814/abstract/36\">",
"      Bajbouj M, Becker V, Eckel F, et al. Argon plasma coagulation of cervical heterotopic gastric mucosa as an alternative treatment for globus sensations. Gastroenterology 2009; 137:440.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2240 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-F0BCE44B44-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_19_21814=[""].join("\n");
var outline_f21_19_21814=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480081804\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480081797\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Gastroesophageal reflux disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19946665\">",
"      Visceral hypersensitivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Upper esophageal sphincter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Psychologic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Stress",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2240\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2240|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/18/11563\" title=\"table 1\">",
"      Disorders associated globus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/18/2346?source=related_link\">",
"      Benign lesions of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=related_link\">",
"      Clinical manifestations and diagnosis of achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26247?source=related_link\">",
"      Esophageal multichannel intraluminal impedance testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_19_21815="Gastroduodenal Crohns UGI";
var content_f21_19_21815=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77013%7EGAST%2F78617%7EGAST%2F81537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77013%7EGAST%2F78617%7EGAST%2F81537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Crohn's disease of the upper gastrointestinal tract",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper gastrointestinal series in a patient with gastroduodenal Crohn's disease shows antral narrowing (small arrow) and two duodenal strictures (large arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the American Gastroenterological Association&copy;. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner-Fenwick, Inc at 1-800-432-8433.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Crohn's disease of the stomach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 344px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This upper gastrointestinal series, performed in a young man with known Crohn's disease of the terminal ileum shows numerous rounded filling defects in the stomach produced by edematous mucosa. In some of these areas, small central collections of barium are demonstrated (arrow) resulting from superficial erosions. These features are suggestive of Crohn's disease, but may also be seen in patients with peptic ulcer disease, and in viral gastritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal upper GI series",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal air-contrast upper gastrointestinal study showing normal gastric folds and small intestinal anatomy, and no masses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_19_21815=[""].join("\n");
var outline_f21_19_21815=null;
var title_f21_19_21816="Pregnancy in women with diabetic nephropathy";
var content_f21_19_21816=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pregnancy in women with diabetic nephropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/19/21816/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/19/21816/contributors\">",
"     E Albert Reece, MD, PhD, MBA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/19/21816/contributors\">",
"     Carol J Homko, RN, PhD, CDE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/19/21816/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/19/21816/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/19/21816/contributors\">",
"     Michael F Greene, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/19/21816/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/19/21816/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/19/21816/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic nephropathy refers to a progressive disease characterized by proteinuria, hypertension, reduced glomerular filtration rate, and increasing renal failure. It is a critical factor affecting the outcome of pregnancy in diabetic women and is present in approximately 6 percent of pregnant women with type I diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In addition, diabetic nephropathy is closely associated with increased morbidity and mortality due to an excess of cardiovascular deaths and end-stage renal failure.",
"   </p>",
"   <p>",
"    The management and outcome of pregnancy complicated by diabetic nephropathy will be reviewed here. General issues pertaining to the pathogenesis and treatment of diabetic nephropathy in nonpregnant individuals is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=see_link\">",
"     \"Overview of diabetic nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In pregnancy, a diagnosis of diabetic nephropathy is made if there is persistent proteinuria of greater than 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or albuminuria greater than 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in the first 20 weeks of pregnancy in the absence of urinary tract infection. The normal rate of albumin excretion is less than 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (15",
"    <span class=\"nowrap\">",
"     mcg/min).",
"    </span>",
"    Microalbuminuria refers to levels of albuminuria too low to be detected by conventional dipstick methods, generally defined as persistent albumin excretion of 30 to 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (20 to 200",
"    <span class=\"nowrap\">",
"     mcg/min).",
"    </span>",
"    It is usually indicative of incipient diabetic nephropathy, unless there is coexistent renal disease, and can be present for years before overt proteinuria is detected. Macroalbuminuria refers to urinary albumin excretion greater than 300",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=see_link\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=see_link\">",
"     \"Microalbuminuria in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Confounding effects of urine volume on albumin concentration may be avoided by calculation of the albumin-to-creatinine ratio in an untimed urine specimen. A value above 30 mg suggests that albumin excretion is above 30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and microalbuminuria is probably present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFECT OF NEPHROPATHY ON PREGNANCY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pregnancy complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perinatal morbidity and mortality related to diabetic nephropathy have improved significantly in parallel with efforts to achieve stringent glycemic control. Despite good glycemic control, overt nephropathy is associated with a variety of pregnancy complications, such as fetal growth restriction, nonreassuring fetal status, and preeclampsia. As a consequence, preterm delivery and cesarean birth are often required for maternal or fetal indications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Women with overt nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our review of the world literature from 1981 to 1996 found overall perinatal survival in pregnancy complicated by diabetic nephropathy was 95 percent, compared to approximately 99 percent in the general obstetric population [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/3\">",
"     3",
"    </a>",
"    ], with similar rates of survival reported in more current studies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/2,4-7\">",
"     2,4-7",
"    </a>",
"    ]. Preterm delivery occurred in 22 percent of pregnancies and was associated with significant neonatal morbidity (eg, respiratory distress syndrome [20 percent], jaundice [28 percent]). Fetal growth restriction occurred in 15 percent and the overall malformation rate was 8 percent, with little change noted in more recent reports [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/2,4-7\">",
"     2,4-7",
"    </a>",
"    ]. The rates of maternal and perinatal complications are illustrated in the figures (",
"    <a class=\"graphic graphic_figure graphicRef73010 \" href=\"UTD.htm?42/29/43485\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef68924 \" href=\"UTD.htm?31/34/32301\">",
"     figure 2",
"    </a>",
"    ). &nbsp;Maternal overweight appears to be associated with an increased rate of pregnancy complications across varying levels of nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The degree of renal impairment correlates with the risk of pregnancy complications. In one study of 17 women, as an example, women with diabetic nephropathy and normal serum creatinine concentration (group 1) had better perinatal outcomes than those with moderate renal impairment (mean serum creatinine concentration greater than 1.8",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    group 2) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/8\">",
"     8",
"    </a>",
"    ]. Median gestation of pregnancy was 36 &plusmn; 4 weeks in group 1 and 31 &plusmn; 3 weeks in group 2 (p &lt;0.05) and babies in group 1 required neonatal intensive care for a median of 13 days (range 7 to 17) (p &lt;0.05) as compared to group 2 whose median stay was 19 days (range 8 to 271). In another series of 45 women with diabetic nephropathy, women with either a high degree of proteinuria (greater than 3",
"    <span class=\"nowrap\">",
"     g/24",
"    </span>",
"    hours) or a moderately elevated serum creatinine (greater than 1.5",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    had an increased risk of preterm delivery, low birth weight, and preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/9\">",
"     9",
"    </a>",
"    ]. Similar findings have been reported by others [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/5,10,11\">",
"     5,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preeclampsia is the most frequent complication of pregnancy in women with diabetic nephropathy and may be related, in part, to their level of proteinuria in early pregnancy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a large series evaluating the relationship between early-pregnancy proteinuria and later development of preeclampsia (158 normo hypertensive women and 49 women with chronic hypertension), a receiver-operating characteristic curve showed an increased risk of preeclampsia with early-pregnancy proteinuria of 190",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or more [",
"      <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/12\">",
"       12",
"      </a>",
"      ]. The rates of preeclampsia in women with early-pregnancy proteinuria of less than 190",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (group 1), 190 to 499",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (group 2), and &ge;500",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (group 3) were 7, 31, and 38 percent, respectively. This relationship persisted after adjusting for the effects of parity, chronic hypertension, retinopathy, and glycemic control.",
"     </li>",
"     <li>",
"      However, the low risk of preeclampsia in women with a low level of early pregnancy proteinuria was not confirmed by a similar series published 11 years later (including 141 normo hypertensive and 52 hypertensive pregestational diabetics) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/13\">",
"       13",
"      </a>",
"      ]. In this series, the rates of preeclampsia in women with early-pregnancy proteinuria of less than 190",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (group 1), 190 to 499",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (group 2), and &ge;500",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (group 3) were 17, 20, and 32 percent, respectively. There was no significant difference in prevalence of preeclampsia between group 1 and group 2 and no threshold that predicted development of preeclampsia. The relationship persisted in women with chronic hypertension. The proportion of nulliparous women was similar in groups 1 and 2, and higher in group 3. Glycemic control and presence of retinopathy were not considered in the analysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The low prevalence of preeclampsia in group 1 of the first study [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/12\">",
"     12",
"    </a>",
"    ] is comparable to that in the nondiabetic population and is difficult to explain. Since neither study measured albumin excretion, it is possible that a higher proportion of group 1 women in the second series [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/13\">",
"     13",
"    </a>",
"    ] had microalbuminuria, which is predictive of development of preeclampsia (see below). The discordancy could also relate to differences in patient populations or undefined differences in diagnosis and management that have occurred over the past decade.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Women with microalbuminuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microalbuminuria in type I diabetic women also appears to be associated with adverse pregnancy outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. A series of women with diabetes with normal albumin excretion (n = 203), microalbuminuria (n = 26), and overt nephropathy (n = 11) reported preterm birth in 35, 62, and 91 percent, respectively; small for gestational age infants in 2, 4, and 45 percent, respectively; and development of preeclampsia in 6, 42, and 64 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/14\">",
"     14",
"    </a>",
"    ]. Early and stringent antihypertensive therapy has been associated with a reduced risk of early preterm delivery (&lt;34 weeks of gestation) in women with type 1 diabetes with microalbuminuria [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/2,16\">",
"     2,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Long term perinatal effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perinatal survival of infants born to mothers with diabetic nephropathy has been 95 to 100 percent during the past two decades. The high rate of prematurity in this population, however, is associated with an increased risk of long-term morbidity. As an example, a series of 35 infants of mothers with diabetic nephropathy followed for up to ten years following delivery found that four had severe psychomotor retardation and three had mild developmental retardation, primarily associated with prematurity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=see_link\">",
"     \"Infant of a diabetic mother\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EFFECT OF PREGNANCY ON DIABETIC NEPHROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with diabetic nephropathy are at increased risk of renal failure during or after pregnancy and eventual morbidity or death from macrovascular disease. Whether pregnancy causes a worsening of diabetic nephropathy or hastens the progression to end-stage renal disease is controversial. Historically, women with nephropathy, especially those with preexisting hypertension, were discouraged from pregnancy. However, most modern studies have demonstrated that maternal and perinatal outcomes are very good.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal pregnancy is associated with up to a 60 percent increase in glomerular filtration rate and a small increase in urinary protein excretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=see_link\">",
"     \"Renal and urinary tract physiology in normal pregnancy\"",
"    </a>",
"    .) Similarly, in one study of 30 women with type 1 diabetes but no nephropathy, albumin excretion rose almost four-fold to 43",
"    <span class=\"nowrap\">",
"     mcg/min",
"    </span>",
"    (equivalent to 62",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The amount of proteinuria in women with diabetic nephropathy also typically increases as pregnancy progresses, and regresses to or near prepregnancy levels after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/3,19,20\">",
"     3,19,20",
"    </a>",
"    ]. Increased protein excretion also occurs in women with microalbuminuria. In a series of 12 women with microalbuminuria at baseline, urinary protein excretion during pregnancy increased almost seven-fold to a mean of 492",
"    <span class=\"nowrap\">",
"     mcg/min",
"    </span>",
"    (equivalent to 708",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    exceeding 3",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    in four of the women, but returning to baseline in all within 12 weeks after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=see_link\">",
"     \"Pregnancy risks in women with type 1 and type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=see_link\">",
"     \"Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many women experience a temporary decline in renal function during gestation, pregnancy per se does not appear to hasten the natural progression to end-stage renal disease for most women; however, this depends upon the initial degree of renal impairment. Women with mild renal dysfunction (serum creatinine concentration less than 1.4",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    creatinine clearance greater than 80",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    prior to pregnancy are likely to maintain stable renal function throughout pregnancy. However women with moderate to severe renal insufficiency typically show rising creatinine concentrations by the third trimester that may persist postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/3,8\">",
"     3,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of pregnancy on the long-term progression of renal disease is unclear. There is a concern that worsening hypertension, proteinuria, and glomerular filtration rate during pregnancy might accelerate the progression of nephropathy to end-stage renal disease (ESRD) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Women with mild to moderate renal insufficiency generally experience no permanent acceleration in the rate of decline of renal function postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/19,23\">",
"     19,23",
"    </a>",
"    ]. Three studies that examined the fall in creatinine clearance in the years following pregnancy found creatinine clearance fell at an average rate of 8 to 10",
"    <span class=\"nowrap\">",
"     mL/min/year",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/17,24,25\">",
"     17,24,25",
"    </a>",
"    ]. This rate of decline was comparable to that in the general diabetic population.",
"   </p>",
"   <p>",
"    This is also true for women with only microalbuminuria. The Diabetes Control and Complications Trial (DCCT), a multicenter controlled clinical trial studied 190 diabetic women who had 270 pregnancies and 500 diabetic women who did not become pregnant over a follow-up period averaging 6.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/26\">",
"     26",
"    </a>",
"    ]. Pregnancy did not affect the long-term rate of progression of underlying nephropathy, as measured by albumin excretion, in women with microalbuminuria. The EURODIAB IDDM Complications Study also found that pregnancy was not a risk factor for development of microalbuminuria or long-term progression of nephropathy in woman with no nephropathy or microalbuminuria at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, permanent renal damage, including renal failure, may be more common among women with poorly controlled hypertension or moderate to severe renal insufficiency at the onset of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/22,28\">",
"     22,28",
"    </a>",
"    ]. Some of these women appear to require dialysis or kidney transplant sooner than if they had not become pregnant. As an example, a study of 11 women in whom serum creatinine concentrations were &ge;1.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (124",
"    <span class=\"nowrap\">",
"     mumol/L)",
"    </span>",
"    at the onset of pregnancy described stable renal function in 27 percent, transient worsening in 27 percent, and permanent decline in 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/28\">",
"     28",
"    </a>",
"    ]. Identical findings have been reported by others [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar findings have been noted in pregnant women with moderate to severe renal insufficiency from all causes. In one series of 76 women with an initial mean plasma creatinine concentration of 1.9",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (168",
"    <span class=\"nowrap\">",
"     mumol/L),",
"    </span>",
"    10 percent progressed to end-stage renal disease during pregnancy or immediately postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/29\">",
"     29",
"    </a>",
"    ]. The risk of acceleration was highest among those with an initial plasma creatinine concentration above 2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     mumol/L),",
"    </span>",
"    33 versus 2 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11241?source=see_link\">",
"     \"Pregnancy in women with underlying renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although a cohort study from Norway reported an increased risk of end stage renal disease and death in women with both diabetes and either preeclampsia or preterm birth, these outcomes were only observed in primiparous women and were weaker than in women without diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MANAGEMENT PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, women with diabetes mellitus should be evaluated for stage of disease, receive counseling, and achieve good glycemic control prior to pregnancy. Informed women are more motivated to adhere to intensive treatment regimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=see_link\">",
"     \"Pregnancy risks in women with type 1 and type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=see_link\">",
"     \"Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20794?source=see_link\">",
"     \"Medical management of type 1 and type 2 diabetes mellitus in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Preconception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preconceptional care of women with diabetic nephropathy should include evaluation of renal function and staging of nephropathy, if present. A 24-hour urine specimen should be collected for determination of total urine protein excretion and creatinine clearance. Women with incipient or overt diabetic nephropathy who are receiving angiotensin converting enzyme (ACE) inhibitors should be changed to other agents to control hypertension before conception as these agents are teratogenic (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/31\">",
"     31",
"    </a>",
"    ]. Dihydropyridine calcium channel blockers can be useful in such women [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation for heart disease (eg, by electrocardiogram) and retinopathy should also be undertaken before conception. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=see_link\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42501?source=see_link\">",
"     \"Screening for diabetic retinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Treatment of hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, an important question is whether worsening hypertension and proteinuria during pregnancy accelerate progression of diabetic nephropathy to end-stage renal disease. The four major factors that have been associated with the development and progression of diabetic nephropathy are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Microalbuminuria",
"     </li>",
"     <li>",
"      Degree of glycemic control",
"     </li>",
"     <li>",
"      Blood pressure",
"     </li>",
"     <li>",
"      Pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=see_link\">",
"     \"Overview of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interventions such as lowering blood pressure, reducing microalbuminuria, and improving glycemic control have a protective effect on the glomeruli and decrease the rate of decline of glomerular filtration rate (GFR) over the long-term [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/24,34,35\">",
"     24,34,35",
"    </a>",
"    ]. On the other hand, progression of nephropathy increases when blood pressure is poorly controlled. For these reasons, strict blood pressure control is recommended in women with diabetic nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    .) With respect to pregnancy, treatment of hypertension is associated with improved fetal outcome and a decrease in maternal end organ damage [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/9,16,25,33\">",
"     9,16,25,33",
"    </a>",
"    ]. Conversely, suboptimal control of hypertension in women with diabetic nephropathy early in pregnancy is associated with a significant risk of preterm delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Angiotensin converting enzyme inhibitors (ACE) and angiotensin II receptor antagonists are commonly used in nonpregnant diabetics for renoprotection. The effectiveness of these agents is of crucial importance for the obstetrician and perinatologist since they are contraindicated in pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"    </a>",
"    .) However, studies have shown that women treated with ACE inhibitors and intensive metabolic control for three to six months prior to conception maintained a renoprotective effect throughout pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. In addition, prepregnancy treatment was associated with favorable perinatal outcomes.",
"   </p>",
"   <p>",
"    Calcium channel blockers may have similar renal protective effects as ACE inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/32,38-40\">",
"     32,38-40",
"    </a>",
"    ] and do not appear to be associated with an increased risk for congenital malformations when compared to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/36\">",
"     36",
"    </a>",
"    ]. Therefore, these agents are a reasonable option for the treatment of hypertension in pregnant women with diabetic nephropathy, microalbuminuria, or microvascular disease. The general treatment of hypertension and preeclampsia in pregnant women is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link\">",
"     \"Management of hypertension in pregnant and postpartum women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The blood pressure goal in nonpregnant patients with diabetes and proteinuria is less than",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg. We use the same goal during pregnancy; however, there are no data in pregnant women. Blood pressure reduction should be gradual. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Preeclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proteinuria and edema usually increase by the third trimester in most women with diabetic nephropathy, thereby making differential diagnosis difficult. Distinguishing between worsening chronic hypertension and superimposed preeclampsia is important since management is significantly different. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link&amp;anchor=H19#H19\">",
"     \"Preeclampsia: Clinical features and diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delivery is the only treatment for preeclampsia, although some women may be managed conservatively if remote from term. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=see_link\">",
"     \"Preeclampsia: Management and prognosis\"",
"    </a>",
"    .) By comparison, adjustment in antihypertensive medication is the therapy for chronic hypertension. Delivery is not undertaken unless there are additional obstetrical complications (eg, abruption, nonreassuring fetal assessment, severe fetal growth restriction).",
"   </p>",
"   <p>",
"    Low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    has not been shown to significantly reduce the rate of preeclampsia in type 1 diabetics [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21816/abstract/41\">",
"     41",
"    </a>",
"    ]. It is not clear whether this therapy might benefit a subgroup of patients with nephropathy. Preliminary data from our experience has not shown a benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41609?source=see_link\">",
"     \"Prevention of preeclampsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Antenatal care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstetrical management of diabetic pregnancy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35818?source=see_link\">",
"     \"Obstetrical management of pregnancy complicated by pregestational diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with diabetic nephropathy require an intensive program of maternal and fetal evaluation, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial evaluation of serum creatinine and uric acid concentration, blood urea nitrogen (BUN), creatinine clearance, and urine culture.",
"     </li>",
"     <li>",
"      Electrocardiogram",
"     </li>",
"     <li>",
"      Assessment of renal function and retinal status at regular intervals, usually each trimester.",
"     </li>",
"     <li>",
"      Close monitoring of blood pressure, with addition or adjustment of antihypertensive agents as needed. The drugs of choice are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"       methyldopa",
"      </a>",
"      , calcium channel blockers, and beta blockers. Select calcium channel inhibitors, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       Diltiazem",
"      </a>",
"      , induce mild reductions in blood pressure, but have a potent effect on decreasing excess protein excretion.",
"     </li>",
"     <li>",
"      Serial assessment of fetal growth every four to six weeks in the last one-half of pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22906?source=see_link\">",
"       \"Diagnosis of fetal growth restriction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fetal assessment, which may begin as early as 26 weeks of gestation but always by 32 weeks. Daily fetal movement counts are supplemented by evaluation twice weekly with nonstress tests or biophysical profile or a combination of these tests.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preterm delivery can be considered for the usual obstetric indications or for progressive azotemia. Each woman should be evaluated according to her individual clinical situation.",
"   </p>",
"   <p>",
"    There is little benefit in continuing pregnancy beyond 38 completed weeks of gestation if fetal pulmonary maturity can be demonstrated and the cervix is favorable. If the cervix is not favorable, cervical ripening agents may be used or pregnancy may be continued until 39 to 40 weeks if there are no additional complications, such as poor glycemic control, noncompliance, preeclampsia, abnormal fetal growth, history of stillbirth, poorly controlled hypertension, or significantly deteriorating renal function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=see_link\">",
"     \"Principles of labor induction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/62/31714?source=see_link\">",
"       \"Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/45/10966?source=see_link\">",
"       \"Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy is not contraindicated in most women with diabetic nephropathy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Effect of nephropathy on pregnancy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Effect of pregnancy on diabetic nephropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maternal and perinatal outcomes are generally good with tight control of glycemia and blood pressure. Although mortality is low, maternal and neonatal morbidity are increased compared to nondiabetics and diabetic women without nephropathy. The major obstetrical complications are preeclampsia, fetal growth restriction, and preterm birth. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Long term perinatal effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preconceptional treatment with angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in women with microalbuminuria may have benefits that extend through the pregnancy. However, these agents should",
"      <strong>",
"       not",
"      </strong>",
"      be used during pregnancy as they are teratogenic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link\">",
"       \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pregnancy does not appear to accelerate the progression of diabetic nephropathy in women with a mild to moderate decline in renal function. Women with moderate to severe renal impairment (serum creatinine level &gt;1.5",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      proteinuria &gt;3 g in 24 hours) may benefit from renal transplantation or dialysis therapy before initiating pregnancy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Effect of pregnancy on diabetic nephropathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Reece EA, Coustan DR, Gabbe SG. Diabetes in Women: Adolescence, Pregnancy and Menopause, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/2\">",
"      Nielsen LR, M&uuml;ller C, Damm P, Mathiesen ER. Reduced prevalence of early preterm delivery in women with Type 1 diabetes and microalbuminuria--possible effect of early antihypertensive treatment during pregnancy. Diabet Med 2006; 23:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/3\">",
"      Reece EA, Leguizamon G, Homko C. Pregnancy performance and outcomes associated with diabetic nephropathy. Am J Perinatol 1998; 15:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/4\">",
"      Carr DB, Koontz GL, Gardella C, et al. Diabetic nephropathy in pregnancy: suboptimal hypertensive control associated with preterm delivery. Am J Hypertens 2006; 19:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/5\">",
"      Young EC, Pires ML, Marques LP, et al. Effects of pregnancy on the onset and progression of diabetic nephropathy and of diabetic nephropathy on pregnancy outcomes. Diabetes Metab Syndr 2011; 5:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/6\">",
"      Yogev Y, Chen R, Ben-Haroush A, et al. Maternal overweight and pregnancy outcome in women with Type-1 diabetes mellitus and different degrees of nephropathy. J Matern Fetal Neonatal Med 2010; 23:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/7\">",
"      Dunne FP, Chowdhury TA, Hartland A, et al. Pregnancy outcome in women with insulin-dependent diabetes mellitus complicated by nephropathy. QJM 1999; 92:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/8\">",
"      Mackie AD, Doddridge MC, Gamsu HR, et al. Outcome of pregnancy in patients with insulin-dependent diabetes mellitus and nephropathy with moderate renal impairment. Diabet Med 1996; 13:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/9\">",
"      Gordon M, Landon MB, Samuels P, et al. Perinatal outcome and long-term follow-up associated with modern management of diabetic nephropathy. Obstet Gynecol 1996; 87:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/10\">",
"      Khoury JC, Miodovnik M, LeMasters G, Sibai B. Pregnancy outcome and progression of diabetic nephropathy. What's next? J Matern Fetal Neonatal Med 2002; 11:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/11\">",
"      Howarth C, Gazis A, James D. Associations of Type 1 diabetes mellitus, maternal vascular disease and complications of pregnancy. Diabet Med 2007; 24:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/12\">",
"      Combs CA, Rosenn B, Kitzmiller JL, et al. Early-pregnancy proteinuria in diabetes related to preeclampsia. Obstet Gynecol 1993; 82:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/13\">",
"      How HY, Sibai B, Lindheimer M, et al. Is early-pregnancy proteinuria associated with an increased rate of preeclampsia in women with pregestational diabetes mellitus? Am J Obstet Gynecol 2004; 190:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/14\">",
"      Ekbom P, Damm P, Feldt-Rasmussen B, et al. Pregnancy outcome in type 1 diabetic women with microalbuminuria. Diabetes Care 2001; 24:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/15\">",
"      Jensen DM, Damm P, Ovesen P, et al. Microalbuminuria, preeclampsia, and preterm delivery in pregnant women with type 1 diabetes: results from a nationwide Danish study. Diabetes Care 2010; 33:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/16\">",
"      Nielsen LR, Damm P, Mathiesen ER. Improved pregnancy outcome in type 1 diabetic women with microalbuminuria or diabetic nephropathy: effect of intensified antihypertensive therapy? Diabetes Care 2009; 32:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/17\">",
"      Kimmerle R, Zass RP, Cupisti S, et al. Pregnancies in women with diabetic nephropathy: long-term outcome for mother and child. Diabetologia 1995; 38:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/18\">",
"      Biesenbach G, Zazgornik J, St&ouml;ger H, et al. Abnormal increases in urinary albumin excretion during pregnancy in IDDM women with pre-existing microalbuminuria. Diabetologia 1994; 37:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/19\">",
"      Kitzmiller JL, Brown ER, Phillippe M, et al. Diabetic nephropathy and perinatal outcome. Am J Obstet Gynecol 1981; 141:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/20\">",
"      Irfan S, Arain TM, Shaukat A, Shahid A. Effect of pregnancy on diabetic nephropathy and retinopathy. J Coll Physicians Surg Pak 2004; 14:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/21\">",
"      Biesenbach G, Grafinger P, St&ouml;ger H, Zazgornik J. How pregnancy influences renal function in nephropathic type 1 diabetic women depends on their pre-conceptional creatinine clearance. J Nephrol 1999; 12:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/22\">",
"      Biesenbach G, St&ouml;ger H, Zazgornik J. Influence of pregnancy on progression of diabetic nephropathy and subsequent requirement of renal replacement therapy in female type I diabetic patients with impaired renal function. Nephrol Dial Transplant 1992; 7:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/23\">",
"      Reece EA, Winn HN, Hayslett JP, et al. Does pregnancy alter the rate of progression of diabetic nephropathy? Am J Perinatol 1990; 7:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/24\">",
"      Miodovnik M, Rosenn BM, Khoury JC, et al. Does pregnancy increase the risk for development and progression of diabetic nephropathy? Am J Obstet Gynecol 1996; 174:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/25\">",
"      Reece EA, Leguizamon G, Homko C. Stringent controls in diabetic nephropathy associated with optimization of pregnancy outcomes. J Matern Fetal Med 1998; 7:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/26\">",
"      Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care 2000; 23:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/27\">",
"      V&eacute;rier-Mine O, Chaturvedi N, Webb D, Fuller JH. Is pregnancy a risk factor for microvascular complications? The EURODIAB Prospective Complications Study. Diabet Med 2005; 22:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/28\">",
"      Purdy LP, Hantsch CE, Molitch ME, et al. Effect of pregnancy on renal function in patients with moderate-to-severe diabetic renal insufficiency. Diabetes Care 1996; 19:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/29\">",
"      Jones DC, Hayslett JP. Outcome of pregnancy in women with moderate or severe renal insufficiency. N Engl J Med 1996; 335:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/30\">",
"      Sandvik MK, Iversen BM, Irgens LM, et al. Are adverse pregnancy outcomes risk factors for development of end-stage renal disease in women with diabetes? Nephrol Dial Transplant 2010; 25:3600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/31\">",
"      Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354:2443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/32\">",
"      American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care 2013; 36 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/33\">",
"      Leguizamon G, Reece EA. Effect of medical therapy on progressive nephropathy: influence of pregnancy, diabetes and hypertension. J Matern Fetal Med 2000; 9:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/34\">",
"      Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994; 271:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/35\">",
"      Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/36\">",
"      Hod M, van Dijk DJ, Karp M, et al. Diabetic nephropathy and pregnancy: the effect of ACE inhibitors prior to pregnancy on fetomaternal outcome. Nephrol Dial Transplant 1995; 10:2328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/37\">",
"      Bar J, Chen R, Schoenfeld A, et al. Pregnancy outcome in patients with insulin dependent diabetes mellitus and diabetic nephropathy treated with ACE inhibitors before pregnancy. J Pediatr Endocrinol Metab 1999; 12:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/38\">",
"      Magee LA, Schick B, Donnenfeld AE, et al. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Am J Obstet Gynecol 1996; 174:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/39\">",
"      Jerums G, Allen TJ, Tsalamandris C, Cooper ME. Angiotensin converting enzyme inhibition and calcium channel blockade in incipient diabetic nephropathy. The Melbourne Diabetic Nephropathy Study Group. Kidney Int 1992; 41:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/40\">",
"      Bakris GL, Copley JB, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996; 50:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21816/abstract/41\">",
"      Sibai BM. Risk factors, pregnancy complications, and prevention of hypertensive disorders in women with pregravid diabetes mellitus. J Matern Fetal Med 2000; 9:62.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4809 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-B2407C6BAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_19_21816=[""].join("\n");
var outline_f21_19_21816=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFECT OF NEPHROPATHY ON PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pregnancy complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Women with overt nephropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Women with microalbuminuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Long term perinatal effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EFFECT OF PREGNANCY ON DIABETIC NEPHROPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Proteinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Renal function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MANAGEMENT PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Preconception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Treatment of hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Antenatal care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4809\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4809|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/29/43485\" title=\"figure 1\">",
"      Maternal complications of diabetic nephropathy in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/34/32301\" title=\"figure 2\">",
"      Perinatal complications of maternal diabetic nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22906?source=related_link\">",
"      Diagnosis of fetal growth restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=related_link\">",
"      Infant of a diabetic mother",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20794?source=related_link\">",
"      Medical management of type 1 and type 2 diabetes mellitus in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=related_link\">",
"      Microalbuminuria in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=related_link\">",
"      Microalbuminuria in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35818?source=related_link\">",
"      Obstetrical management of pregnancy complicated by pregestational diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=related_link\">",
"      Overview of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/45/10966?source=related_link\">",
"      Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/62/31714?source=related_link\">",
"      Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11241?source=related_link\">",
"      Pregnancy in women with underlying renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=related_link\">",
"      Pregnancy risks in women with type 1 and type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=related_link\">",
"      Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41609?source=related_link\">",
"      Prevention of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=related_link\">",
"      Principles of labor induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=related_link\">",
"      Renal and urinary tract physiology in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42501?source=related_link\">",
"      Screening for diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=related_link\">",
"      Treatment of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=related_link\">",
"      What is goal blood pressure in the treatment of hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_19_21817="What's new in cardiovascular medicine";
var content_f21_19_21817=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   What's new in cardiovascular medicine",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/19/21817/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/19/21817/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/19/21817/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/19/21817/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/19/21817/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     ARRHYTHMIAS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Pacemaker insertion for asymptomatic Mobitz type I second degree AV block",
"    </span>",
"   </p>",
"   <p>",
"    The optimal management of asymptomatic patients with Mobitz type I second degree AV block is controversial, with European guidelines recommending for and American guidelines against pacemaker placement. Among a cohort of 299 mostly male patients (mean age 75) with Mobitz type I AV block followed for an average of 3.3 years, 59 percent remained asymptomatic, while 41 percent required a pacemaker for symptomatic bradycardia or progression to higher grade AV block [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients who received a pacemaker had a 46 percent reduction in total mortality compared to those patients who remained asymptomatic and did not receive a pacemaker. However, because this was a single center study of mostly elderly male patients with a high mortality rate, we feel these data are insufficient to recommend pacemaker placement for all patients with Mobitz type I second degree AV block. For the majority of patients with Mobitz type I AV block and",
"    <strong>",
"     asymptomatic",
"    </strong>",
"    bradycardia, we still favor",
"    <strong>",
"     not",
"    </strong>",
"    implanting a permanent pacemaker. Exceptions include patients with infranodal AV block and some elderly patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18087?source=see_link&amp;anchor=H10101639#H10101639\">",
"     \"Second degree atrioventricular block: Mobitz type I (Wenckebach block)\", section on 'Asymptomatic patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Azithromycin and torsades de pointes",
"    </span>",
"   </p>",
"   <p>",
"    In 2013, the US Food and Drug Administration issued a warning about the risk of QT interval prolongation and potentially fatal torsades de pointes among patients taking azithromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients at particular risk include those with existing QT prolongation, hypokalemia, hypomagnesemia, significant bradycardia, and those receiving certain antiarrhythmic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The warning was based on a review&nbsp;following the publication of a study that showed an increased risk of death in patients receiving azithromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/5\">",
"     5",
"    </a>",
"    ]. Clinicians should assess the risk of torsades de pointes when considering antibiotic treatment options for patients at risk for cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/2\">",
"     2",
"    </a>",
"    ]. Other macrolides and certain non-macrolides, such as fluoroquinolones, also have the potential for prolonging the QT interval. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=see_link&amp;anchor=H22#H22\">",
"     \"Azithromycin, clarithromycin, and telithromycin\", section on 'Long QT syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Safety of competitive athletic participation in patients with LQTS",
"    </span>",
"   </p>",
"   <p>",
"    The long QT syndrome (LQTS), a genetic disorder whose phenotypic expression is a prolonged corrected QT interval on the electrocardiogram (ECG), has been associated with a significant risk for ventricular arrhythmias and sudden cardiac death (SCD). As of 2005, both European and American professional societies have recommended significant restrictions in activity in patients with LQTS to reduce the risk of ventricular arrhythmias and SCD. However, among 130 patients (out of a total cohort of 353 patients) with LQTS who remained active in competitive athletics and were followed for an average of 5.5 years, there were no cardiac events among 70 genotype",
"    <span class=\"nowrap\">",
"     positive/phenotype",
"    </span>",
"    negative patients (ie, QT interval within the normal range)&nbsp;and only one arrhythmic event among 60 genotype",
"    <span class=\"nowrap\">",
"     positive/phenotype",
"    </span>",
"    positive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/6\">",
"     6",
"    </a>",
"    ]. While our experts continue to recommend restricted athletic participation in accordance with the Bethesda Conference recommendations, these cohort data are reassuring that continued athletic participation in patients with genotype positive LQTS is relatively safe.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=see_link&amp;anchor=H28#H28\">",
"     \"Risk of sudden cardiac death in athletes\", section on 'Congenital long QT syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Oxycodone toxicity and QTc prolongation",
"    </span>",
"   </p>",
"   <p>",
"    Opioids are well known to cause depressed mental status and respirations. Additional toxicities may be specific to particular agents. Methadone has been associated with an increase in the QTc interval and torsade des pointes, leading to a safety alert&nbsp;in the U.S. 2006. A new retrospective review of 137 patients with oxycodone overdose found associated bradycardia in 24 patients and prolongation of the QTc interval&nbsp;in 20 of the 116 patients for whom electrocardiograms were available&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=see_link&amp;anchor=H11#H11\">",
"     \"Opioid intoxication in adults\", section on 'Electrocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Efficacy of radiofrequency catheter ablation for atrial fibrillation",
"    </span>",
"   </p>",
"   <p>",
"    Radiofrequency catheter ablation (RFA) is used to prevent episodes of atrial fibrillation (AF) in patients who have failed antiarrhythmic drug therapy. The best available evidence on the rates of AF after RFA come from the DISCERN AF study, which evaluated episodes of symptomatic and asymptomatic AF before and after RFA in 50 patients using an implantable cardiac monitor [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/8\">",
"     8",
"    </a>",
"    ]. The total atrial arrhythmia burden was significantly reduced by 86 percent from a mean of 2.0 hours per day per patient before to 0.3 hours per day after RFA. After 18 months and a mean of 1.4 ablations, only 58 percent of patients were symptom free. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link&amp;anchor=H22#H22\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\", section on 'AF recurrence after three months'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Apixaban for prevention of embolic events in atrial fibrilllation",
"    </span>",
"   </p>",
"   <p>",
"    Apixaban has been approved by the US Food and Drug Administration and the European Medicines Agency for use in patients with atrial fibrillation to reduce the risk of stroke and systemic embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Approval was based on the results of the large randomized ARISTOTLE trial, which found that apixaban was non-inferior to warfarin in terms of efficacy and superior in terms of safety [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/11\">",
"     11",
"    </a>",
"    ]. In patients with atrial fibrillation who meet criteria for anticoagulation, we prefer either a factor Xa inhibitor (apixaban or rivaroxaban) or a direct thrombin inhibitor (dabigatran) to warfarin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H147982962#H147982962\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Apixaban'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H485506384#H485506384\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Indications for and choice of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bleeding rates with warfarin and dabigatran in atrial fibrillation",
"    </span>",
"   </p>",
"   <p>",
"    Despite favorable results in the initial randomized trials, post-marketing reports have raised concerns that patients with atrial fibrillation may have a higher rate of serious bleeding with dabigatran than warfarin. In November 2012, the US Food and Drug Administration issued a statement that a review of information from insurance claims and administrative data sources suggested that the rate of bleeding with dabigatran did not appear to be higher than with warfarin in patients who were using either drug for the first time [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H147982501#H147982501\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Studies of anticoagulant monotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Radiofrequency catheter ablation as primary therapy for atrial fibrillation",
"    </span>",
"   </p>",
"   <p>",
"    For most patients with paroxysmal atrial fibrillation who wish to pursue a rhythm rather than a rate control strategy, radiofrequency catheter ablation (RFA) is performed after antiarrhythmic drug therapy has failed. The MANTRA-PAF trial evaluated the potential role of RFA as first-line therapy and found that it was as safe and as effective as antiarrhythmic drug therapy for the long-term maintenance of sinus rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, patients had fewer symptomatic episodes. While promising, we believe that the evidence is not strong enough to warrant a recommendation to prefer RFA as primary therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link&amp;anchor=H27#H27\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\", section on 'Comparison to antiarrhythmic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Optimal programming for primary prevention ICDs",
"    </span>",
"   </p>",
"   <p>",
"    The optimal strategy for implantable cardioverter-defibrillator (ICD) programming, until now, has been to deliver antitachycardia therapy (either pacing or shocks) with minimal delay for any sustained ventricular arrhythmia. In MADIT-RIT, 1500 patients receiving an ICD for primary prevention were randomly assigned to one of three different ICD programming and therapy strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Conventional\" therapy programming &ndash; 2.5 second delay at rates of 170 to 199 beats per minute; 1 second delay at rates of 200 or more beats per minute.",
"     </li>",
"     <li>",
"      Delayed therapy programming &ndash; 60 second delay at rates of 170 to 199 beats per minute; 12 second delay at rates of 200 to 249 beats per minute; 2.5 second delay at rates of 250 or more beats per minute.",
"     </li>",
"     <li>",
"      High-rate therapy programming &ndash; No therapy at rates of 170 to 199 beats per minutes; 2.5 second delay at rates of 200 or more beats per minute.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both high-rate and delayed therapy programming led to significant reductions in the primary outcome of inappropriate ICD therapies; reduced mortality was also seen with both strategies but was statistically significant only with high-rate programming. In patients receiving an ICD for primary prevention, we recommend strategies that delay therapy or only institute therapy for very high heart rates, rather than a \"conventional\" ICD strategy that rapidly administers therapy with minimal delay. For the two alternative strategies investigated in MADIT-RIT, we suggest using the high-rate therapy programming strategy rather than the delayed therapy programming strategy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link&amp;anchor=H9233111#H9233111\">",
"     \"General principles of the implantable cardioverter-defibrillator\", section on 'Optimal ICD programming'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CORONARY ARTERY BYPASS GRAFT SURGERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Off&ndash; compared to on-pump CABG",
"    </span>",
"   </p>",
"   <p>",
"    Older studies have suggested similar outcomes between off&ndash; and on-pump coronary artery bypass graft surgery (CABG). The large,&nbsp;randomized CORONARY and GOPCABE trials found no significant difference between the two techniques at 30 days and 1 year for a composite outcome including death, stroke, myocardial infarction, or new renal failure requiring dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, there was a trend toward a higher rate of revascularization with off-pump CABG. We prefer the on-pump&nbsp;approach for most patients undergoing CABG. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37031?source=see_link&amp;anchor=H5#H5\">",
"     \"Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes\", section on 'Compared to on-pump CABG'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CORONARY HEART DISEASE, ACUTE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Time to first cardiac rehabilitation visit",
"    </span>",
"   </p>",
"   <p>",
"    Despite the benefits of cardiac rehabilitation programs for patients with coronary heart disease, including those who have had a myocardial infarction or have undergone revascularization, participation rates are low. A single-blind trial randomly assigned 148 patients to an appointment for cardiac rehabilitation orientation either within the initial 10 days or at 35 days of a nonsurgical qualifying CAD diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/17\">",
"     17",
"    </a>",
"    ]. The median time to orientation was 8.5 and 42 days and the attendance rate was significantly higher in the group that received appointments in the shorter time frame (77 versus 59 percent, respectively). We suggest that early appointments for cardiac rehabilitation be arranged for qualifying patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=see_link&amp;anchor=H870866319#H870866319\">",
"     \"Components of cardiac rehabilitation and exercise prescription\", section on 'Timing of first visit'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Blood transfusion thresholds for acute upper GI bleeding",
"    </span>",
"   </p>",
"   <p>",
"    The decision to initiate blood transfusions in patients with acute upper gastrointestinal bleeding is based on the rapidity of bleeding and the patients' comorbid conditions. A randomized trial of patients with and without cardiovascular disease suggests that in patients who are not at increased risk for complications from anemia, outcomes are improved if a lower hemoglobin threshold (&lt;7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    rather than &lt;9",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    is used for initiating blood transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients transfused when the hemoglobin was &lt;7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    had lower mortality rates, were less likely to have further bleeding, and were less likely to suffer complications.",
"    <br/>",
"    <br/>",
"    We recommend giving blood transfusions to maintain the hemoglobin at &ge;7",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    rather than &ge;9",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    for the majority of patients with acute upper gastrointestinal bleeding who do not have significant comorbid illnesses. However, patients with active bleeding and hypovolemia may require blood transfusion despite an apparently normal hemoglobin. Additionally, we suggest transfusing to maintain the hemoglobin at &ge;9",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    for patients at increased risk of adverse events in the setting of significant anemia, such as those with unstable coronary artery disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link&amp;anchor=H5079586#H5079586\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\", section on 'Blood transfusions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction\", section on 'Blood transfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CORONARY HEART DISEASE, STABLE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cardiotoxicity in women with breast cancer after radiation therapy",
"    </span>",
"   </p>",
"   <p>",
"    A&nbsp;case-control study of women treated for breast cancer with surgery and radiation therapy (RT) found that incidental radiation to the heart is associated with an increased risk&nbsp;for a significant coronary event (myocardial infarction, revascularization, or death from ischemic heart disease)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/19\">",
"     19",
"    </a>",
"    ].&nbsp;The increased risk can be seen after relatively-low doses of radiation and the presence of cardiac risk factors markedly increased the impact of radiation. Despite this, the absolute risk associated with RT appears to be small and to be outweighed by the benefits in patients for whom radiation is typically recommended.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=see_link&amp;anchor=H8#H8\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\", section on 'Effect of radiation dose to the heart'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Duration of beta blocker after myocardial infarction",
"    </span>",
"   </p>",
"   <p>",
"    Although beta blocker (BB) therapy reduces mortality in patients with recent myocardial infarction (MI), the optimal duration of beta blocker therapy after MI is unknown. Beta blocker therapy is continued indefinitely for many patients,&nbsp;based on studies performed in the 1980s and 1990s. A 2013 observational study evaluated outcomes in&nbsp;over 5000&nbsp;patients with ST-elevation MI treated with primary percutaneous coronary intervention&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/20\">",
"     20",
"    </a>",
"    ]. Adjusted mortality rates over approximately four years&nbsp;did not differ between patients who did or did not continue&nbsp;BB therapy. However, subgroup analyses revealed that BB treatment was associated with a significantly lower mortality for high-risk patients, such as those with heart failure. We believe the available evidence supports the use of&nbsp;beta blockers in patients with MI for as long as three years. We make a weak recommendation for BB beyond three years in patients with high-risk features such as cardiogenic shock, heart failure, or chronic kidney disease.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=see_link&amp;anchor=H346544189#H346544189\">",
"     \"Beta blockers in the management of acute coronary syndrome\", section on 'Duration of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     New stable ischemic heart disease guidelines",
"    </span>",
"   </p>",
"   <p>",
"    A multisociety guideline for the diagnosis and management of patients with stable ischemic heart disease has been published and is referenced in multiple topics [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The guideline includes recommendations, with which we agree, that most patients with suspected stable ischemic heart disease undergo stress testing to confirm the diagnosis and to gain prognostic information and that beta blockers are first line therapy to reduce anginal episodes and improve exercise tolerance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=see_link\">",
"     \"Overview of the care of patients with stable ischemic heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     HEART FAILURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Erythropoiesis stimulating agents in heart failure",
"    </span>",
"   </p>",
"   <p>",
"    The available evidence does not support the use of erythropoiesis stimulating agents to treat anemia in patients with heart failure. The best evidence on the lack of efficacy and risk of complications of such treatment in this population comes from the RED-HF trial which randomly assigned 2278 patients with systolic heart failure to treatment with either darbepoetin alfa or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/23\">",
"     23",
"    </a>",
"    ]. Darbepoetin alfa and placebo-treated groups had similar rates of the primary outcome of death from any cause or hospitalization for worsening heart failure at median 28 months follow-up. Rates of thromboembolic adverse events were more frequent in the darbepoetin alfa-treated group (13.5 versus 10.0 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1705?source=see_link&amp;anchor=H15#H15\">",
"     \"Impact of anemia in patients with heart failure\", section on 'Erythropoiesis stimulating agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Ultrafiltration in acute decompensated heart failure",
"    </span>",
"   </p>",
"   <p>",
"    The efficacy and safety of ultrafiltration in patients with acute decompensated heart failure has been evaluated in a few randomized trials. In CARRESS-HF, 188 patients with acute decompensated heart failure, worsened renal function, and persistent congestion were randomly assigned to stepped pharmacologic therapy or ultrafiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/24\">",
"     24",
"    </a>",
"    ]. Ultrafiltration was an effective method for fluid volume removal that provided similar amounts of weight loss to stepped pharmacologic therapy, but it was inferior to stepped pharmacologic therapy for preservation of renal function at 96 hours and was associated with a higher rate of adverse events. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34698?source=see_link&amp;anchor=H26#H26\">",
"     \"Treatment of acute decompensated heart failure: Components of therapy\", section on 'Ultrafiltration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     LIPID DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     CETP inhibition in patients at high risk for cardiovascular disease",
"    </span>",
"   </p>",
"   <p>",
"    Inhibition of cholesteryl ester transfer protein (CETP) function with torcetrapib, anacetrapib, evacetrapib, or dalcetrapib leads to a rise in HDL-cholesterol(C) levels as well as other favorable effects on lipids. However, such an effect on HDL-C has not yet been shown to lower the risk of cardiovascular disease events in individuals at increased risk. The dal-OUTCOMES trial, which randomly assigned acute coronary syndrome patients to dalcetrapib or placebo, was terminated early for futility as there was no significant difference in the two groups with regard to the primary composite end point of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, unstable angina, or cardiac arrest with resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39978?source=see_link&amp;anchor=H32#H32\">",
"     \"HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels\", section on 'Dalcetrapib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Monoclonal antibody to PCSK9 in patients with drug-resistant hypercholesterolemia",
"    </span>",
"   </p>",
"   <p>",
"    Proprotein convertase subtilisin kexin 9 (PCKS9) is a serine protease that leads to the degradation of low density lipoprotein (LDL) receptors and increased LDL-cholesterol levels. In four independent, new randomized trials, differing patient groups with hypercholesterolemia were randomly assigned to receive a human monoclonal antibody to PCSK9 (AMG 145) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. LDL-cholesterol levels were lowered by as much as 40 to 60 percent with AMG 145 compared to placebo, including in patients on maximal tolerated doses of statin therapy. Phase III trials with several years of follow-up are needed to evaluate the impact of treatment with AMG 145 on clinical outcomes and long-term safety. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/5/10329?source=see_link&amp;anchor=H550824534#H550824534\">",
"     \"Treatment of drug-resistant hypercholesterolemia\", section on 'Monoclonal antibody to PCSK9'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     MYOPERICARDIAL DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Pericardiectomy for recurrent pericarditis",
"    </span>",
"   </p>",
"   <p>",
"    Recurrent pericarditis, a recurrence or persistence of the symptoms of acute pericarditis thought to be autoimmune in nature, typically requires a prolonged course of medical therapy. While treatment with pericardiectomy is available for patients with refractory symptoms, the surgery is not universally successful and has been considered as high risk for morbidity and mortality. Among a cohort of 184 patients with chronic recurrent pericarditis (mean six to seven relapses) treated at a single referral center and followed for an average of 5.5 years, the 58 patients who underwent pericardiectomy fared well post-operatively (no immediate deaths, only two major complications) and had significantly fewer relapses (9 versus 29 percent in the medical treatment group) and similar survival as the 126 medically treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/30\">",
"     30",
"    </a>",
"    ]. Pericardiectomy does appear to be a safe and frequently effective treatment option when performed by experienced surgeons in a high-volume center, and it should be considered in persons with ongoing symptoms of recurrent pericarditis in spite of medical therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11177?source=see_link&amp;anchor=H14#H14\">",
"     \"Recurrent pericarditis\", section on 'Role of pericardiectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PREVENTIVE CARDIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Aspirin for the primary prevention of cardiovascular disease and cancer",
"    </span>",
"   </p>",
"   <p>",
"    Meta-analyses of randomized trials have shown aspirin to reduce the risk of non-fatal myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/31\">",
"     31",
"    </a>",
"    ],&nbsp;and long-term aspirin use reduces overall cancer risk [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/32\">",
"     32",
"    </a>",
"    ]. While several published guidelines have considered the benefit of aspirin for&nbsp;the prevention of either cardiovascular disease (CVD)&nbsp;or cancer versus&nbsp;the risk of increased bleeding, most have not addressed the&nbsp;potential net benefit of aspirin in preventing both CVD and cancer.&nbsp;A meta-analysis addressing this combined outcome suggests that aspirin use in 1000 average risk patients at age 60 years would be expected to result, over a 10-year period, in&nbsp;six fewer deaths, 19 fewer non-fatal myocardial infarctions, 14 fewer cancers, and 16 more major bleeding events (",
"    <a class=\"graphic graphic_table graphicRef86941 \" href=\"UTD.htm?39/47/40702\">",
"     table 1",
"    </a>",
"    ).&nbsp;For individuals age 50 years or greater without excess bleeding risks, we suggest daily aspirin at a dose of 75 to 100 mg. Patients who are more concerned about the bleeding risks than the potential benefits may reasonably choose to not take aspirin for primary prevention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23529?source=see_link&amp;anchor=H1761594#H1761594\">",
"     \"Aspirin in the primary prevention of cardiovascular disease and cancer\", section on 'Recommendations for primary prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     REVASCULARIZATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Five year results of the SYNTAX trial",
"    </span>",
"   </p>",
"   <p>",
"    The SYNTAX trial, which&nbsp;randomly assigned 1800 patients with three-vessel or left main coronary artery disease to either coronary artery bypass graft surgery&nbsp;(CABG) or percutaneous coronary intervention, found that the composite outcome at five years&nbsp;(rate of major adverse cardiac and cerebrovascular events) occurred less often with CABG, consistent with findings at three years&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. This benefit was seen predominantly in patients with more complex disease as assessed by the&nbsp;SYNTAX score. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31576?source=see_link&amp;anchor=H17#H17\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\", section on 'SYNTAX trial'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Same-day discharge after uncomplicated PCI",
"    </span>",
"   </p>",
"   <p>",
"    We believe it is reasonable to discharge low-risk percutaneous coronary artery intervention (PCI) patients after four to eight hours of observation if no complications or concerns have arisen.&nbsp;In a&nbsp;2013 meta-analysis of five randomized trials and eight observational studies, which&nbsp;compared same-day discharge to overnight hospitalization, there was no significant difference between the two approaches with regard to major adverse cardiovascular events or rehospitalization&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24889?source=see_link&amp;anchor=H20877078#H20877078\">",
"     \"General principles of the use of intracoronary stents\", section on 'Timing of discharge'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     PCI without on-site cardiac surgery",
"    </span>",
"   </p>",
"   <p>",
"    It appears reasonable to perform elective percutaneous coronary intervention (PCI) at hospitals without on-site cardiac surgical services when institutional and operator quality are high. The MASS COMM trial randomly assigned over 3600 patients with indications for nonemergency PCI, who presented at&nbsp; hospitals without on-site cardiac surgery, to undergo PCI at that hospital or a hospital with cardiac surgery services [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/36\">",
"     36",
"    </a>",
"    ]. PCI procedures performed at hospitals without on-site cardiac surgery were noninferior with regard to the primary outcome of major adverse cardiac events at 30 days and at 12 months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link&amp;anchor=H4#H4\">",
"     \"Periprocedural complications of percutaneous coronary intervention\", section on 'Absence of on-site cardiac surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Platelet monitoring to adjust antiplatelet therapy at PCI",
"    </span>",
"   </p>",
"   <p>",
"    It is unknown whether testing of platelet function and adjustment of antiplatelet therapy as needed, before and after percutaneous coronary intervention (PCI) with stenting, improves clinical outcomes. The ARCTIC trial randomly assigned patients scheduled for coronary stenting and receiving dual antiplatelet therapy to a strategy of platelet-function monitoring (before and after PCI) or no monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/37\">",
"     37",
"    </a>",
"    ]. Patients with high platelet reactivity were administered clopidogrel, prasugrel, or aspirin and glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors during the PCI. No significant difference in the rate of the primary composite end point (death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization at one year) was found, supporting our recommendation to not routinely perform platelet-function testing in patients undergoing PCI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=see_link\">",
"     \"Nonresponse and resistance to clopidogrel\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Selection of stent type in acute STEMI",
"    </span>",
"   </p>",
"   <p>",
"    Drug-eluting stents (DES) are used in preference to bare-metal stents (BMS) in many stable patients undergoing percutaneous coronary intervention (PCI) because they reduce the need for repeat target vessel revascularization without a significant increase in the cumulative rate of adverse outcomes. Similar findings have been found in studies of patients undergoing primary PCI for ST-elevation myocardial infarction (STEMI); most of these studies compared first generation DES to BMS.",
"    <br/>",
"    <br/>",
"    The EXAMINATION and COMFORTABLE AMI trials randomly assigned STEMI patients to one of two second generation DES (an everolimus-eluting or a biolimus&ndash;eluting stent, respectively) or a BMS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Both studies found a lower rate of the need for target",
"    <span class=\"nowrap\">",
"     vessel/lesion",
"    </span>",
"    revascularization and suggested a lower rate of definite stent thrombosis with the DES. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31721?source=see_link&amp;anchor=H24756048#H24756048\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management\", section on 'Selection of stent type'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Bilateral internal thoracic artery grafting in patients with diabetes",
"    </span>",
"   </p>",
"   <p>",
"    While all patients with diabetes undergoing coronary artery bypass grafting should receive an internal thoracic (mammary) artery (ITA) graft to improve survival, it has been uncertain whether bilateral ITA grafting would add further benefit. Based on the results of two observational studies, which demonstrated significantly higher rates of long-term survival for bilateral ITA grafts compared with single grafts, we suggest that bilateral ITA grafting be performed in many patients with diabetes who require coronary revascularization, particularly those younger than age 70 to 75 years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=see_link&amp;anchor=H22#H22\">",
"     \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\", section on 'Internal thoracic artery grafts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Stenting versus CABG in patients with diabetes and multivessel coronary artery disease",
"    </span>",
"   </p>",
"   <p>",
"    The evidence to guide the choice of revascularization between percutaneous intervention (PCI) with stenting and coronary artery bypass graft surgery (CABG) in patients with diabetes and multivessel coronary artery disease was limited prior to the publication of the FREEDOM trial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/42\">",
"     42",
"    </a>",
"    ]. In FREEDOM, 1900 such patients were randomly assigned to either PCI with drug-eluting stents or CABG. The primary composite outcome of death from any cause, nonfatal myocardial infarction, or nonfatal stroke occurred significantly more often in the PCI group at five years. We prefer CABG to PCI with stenting in most patients with diabetes and multivessel disease based on these findings as well as consistent results from older balloon angioplasty and bare metal stent trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=see_link&amp;anchor=H26#H26\">",
"     \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\", section on 'Stenting versus CABG in multivessel disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Drug-coated balloon angioplasty for restenosis following drug-eluting stent",
"    </span>",
"   </p>",
"   <p>",
"    The optimal treatment for restenosis following implantation of drug-eluting stents (DES) is uncertain. The efficacy of drug-eluting balloon angioplasty for patients with DES restenosis was evaluated in the ISAR-DESIRE 3 trial, which found no significant difference between treatment with a paclitaxel-eluting balloon and a paclitaxel-eluting stent in the rate of the primary end point of diameter stenosis at six- to eight-month angiographic follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/43\">",
"     43",
"    </a>",
"    ]. Both of these interventions were superior to balloon angioplasty alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=see_link&amp;anchor=H26#H26\">",
"     \"Intracoronary stent restenosis\", section on 'Drug-coated balloon angioplasty'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     VALVULAR HEART DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Early anticoagulation after implantation of a bioprosthetic aortic valve",
"    </span>",
"   </p>",
"   <p>",
"    The use of short-term vitamin K antagonist therapy early after bioprosthetic valve implantation in patients without thromboembolic risk factors is controversial. An observational study of data from the Danish National Patient Registry found an association between discontinuation of warfarin within six months after bioprosthetic aortic valve implantation and thromboembolic events and cardiovascular death [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/44\">",
"     44",
"    </a>",
"    ]. However, a causal relationship was not established. Given the available evidence, the role of warfarin therapy during the first few months after bioprosthetic valve placement (in patients without other indications for anticoagulation) is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=see_link&amp;anchor=H13#H13\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\", section on 'Early anticoagulation after bioprosthetic valve replacement or mitral valve repair'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Avoid dabigatran with prosthetic heart valves",
"    </span>",
"   </p>",
"   <p>",
"    Based upon interim data from the European RE-ALIGN trial, a safety communication warning was issued in the United States by the Food and Drug Administration regarding increased rates of stroke, myocardial infarction, thrombosis, and major bleeding in patients with mechanical prosthetic heart valves who received anticoagulation with dabigatran compared to those receiving dose-adjusted warfarin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. We recommend against use of direct thrombin inhibitors such as dabigatran&nbsp;in patients with prosthetic heart valves. A vitamin K antagonist is the preferred anticoagulant in patients with prosthetic valves. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=see_link&amp;anchor=H4298909#H4298909\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\", section on 'Oral direct thrombin inhibitors and factor Xa inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     OTHER CARDIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Antiplatelet therapy in patients with CKD",
"    </span>",
"   </p>",
"   <p>",
"    The effectiveness and safety of antiplatelet therapy to prevent cardiovascular disease (CVD) in&nbsp;patients with chronic kidney disease (CKD) is not clear.&nbsp;In a meta-analysis of over 27,000 patients with CKD who participated in 50 randomized trials, antiplatelet therapy&nbsp;(mostly aspirin) reduced the incidence of fatal or non-fatal myocardial infarction as compared with either placebo or no therapy (6.7 versus 7.0 percent, or 3 myocardial infarctions prevented for every 1000 patients treated) but had no effect on stroke or overall mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/48\">",
"     48",
"    </a>",
"    ]. Antiplatelet therapy also increased the rate of major bleeding (4.4 versus 2.9 percent, or 15 additional major bleeding events for every 1000 patients treated). Based upon these data, we suggest that decisions about antiplatelet therapy in patients with CKD be individualized&nbsp;based upon the patient's overall risks for CVD and for bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link&amp;anchor=H14#H14\">",
"     \"Chronic kidney disease and coronary heart disease\", section on 'Antiplatelet therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Triple oral antithrombotic therapy for cardiovascular comorbidities",
"    </span>",
"   </p>",
"   <p>",
"    Some patients with cardiovascular disease, such as those with atrial fibrillation and recent coronary artery stent placement, meet indications for oral anticoagulant and dual&nbsp;antiplatelet therapy (eg clopidogrel plus aspirin). However, such \"triple oral antithrombotic therapy\" (TOAT) is associated with an increased risk of bleeding compared to less agressive therapy. The safety and effacy of clopidogrel alone, compared to&nbsp;clopidogrel plus aspirin, in patients taking long-term&nbsp;warfarin&nbsp;was evaluated&nbsp;in the WOEST trial&nbsp;of&nbsp;over 500&nbsp;patients undergoing&nbsp;percutaneous coronary intervention&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/19/21817/abstract/49\">",
"     49",
"    </a>",
"    ]. After one&nbsp;year,&nbsp;the group assigned to clopidogrel without aspirin&nbsp;experienced lower risk of bleeding as well as the combined secondary end point of death, myocardial infarction, stoke, target-vessel revascularization, and stent thrombosis. While the approach of&nbsp;omitting aspirin from the antithrombotic regimen of patients who have indications for TOAT appears promising,&nbsp;we believe the evidence is not sufficiently strong to recommend such an approach at this time.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13818?source=see_link&amp;anchor=H22848168#H22848168\">",
"     \"Triple antithrombotic therapy in patients with cardiovascular disease\", section on 'After stenting'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/1\">",
"      Coumbe AG, Naksuk N, Newell MC, et al. Long-term follow-up of older patients with Mobitz type I second degree atrioventricular block. Heart 2013; 99:334.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Azithromycin (Zithromax or Zmax): Drug safety communication - risk of potentially fatal heart rhythms. file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm343350.htm?source=govdelivery (Accessed on March 15, 2013).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Zmax (azithromycin extended release) for oral suspension. Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER). file://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm262866.htm (Accessed on May 18, 2012).",
"    </li>",
"    <li>",
"     ZITHROMAX (azithromycin tablets) and(azithromycin for oral suspension) - prescribing information. file://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050710s039,050711s036,050784s023lbl.pdf (Accessed on March 15, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/5\">",
"      Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/6\">",
"      Johnson JN, Ackerman MJ. Return to play? Athletes with congenital long QT syndrome. Br J Sports Med 2013; 47:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/7\">",
"      Berling I, Whyte IM, Isbister GK. Oxycodone overdose causes naloxone responsive coma and QT prolongation. QJM 2013; 106:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/8\">",
"      Verma A, Champagne J, Sapp J, et al. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern Med 2013; 173:149.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333634.htm.",
"    </li>",
"    <li>",
"     file://news.bms.com/press-release/financial-news/eliquisapixaban-approved-europe-prevention-stroke-and-systemic-embolism&amp;t=634890181706594412.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/11\">",
"      Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm282820.htm?source=govdelivery (Accessed on November 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/13\">",
"      Cosedis Nielsen J, Johannessen A, Raatikainen P, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med 2012; 367:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/14\">",
"      Moss AJ, Schuger C, Beck CA, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 2012; 367:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/15\">",
"      Lamy A, Devereaux PJ, Prabhakaran D, et al. Effects of off-pump and on-pump coronary-artery bypass grafting at 1 year. N Engl J Med 2013; 368:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/16\">",
"      Diegeler A, B&ouml;rgermann J, Kappert U, et al. Off-pump versus on-pump coronary-artery bypass grafting in elderly patients. N Engl J Med 2013; 368:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/17\">",
"      Pack QR, Mansour M, Barboza JS, et al. An early appointment to outpatient cardiac rehabilitation at hospital discharge improves attendance at orientation: a randomized, single-blind, controlled trial. Circulation 2013; 127:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/18\">",
"      Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/19\">",
"      Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013; 368:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/20\">",
"      Nakatani D, Sakata Y, Suna S, et al. Impact of beta blockade therapy on long-term mortality after ST-segment elevation acute myocardial infarction in the percutaneous coronary intervention era. Am J Cardiol 2013; 111:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/21\">",
"      Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:e354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/22\">",
"      Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:3097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/23\">",
"      Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013; 368:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/24\">",
"      Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012; 367:2296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/25\">",
"      Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/26\">",
"      Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012; 126:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/27\">",
"      Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012; 308:2497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/28\">",
"      Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012; 380:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/29\">",
"      Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012; 380:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/30\">",
"      Khandaker MH, Schaff HV, Greason KL, et al. Pericardiectomy vs medical management in patients with relapsing pericarditis. Mayo Clin Proc 2012; 87:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/31\">",
"      Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/32\">",
"      Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/33\">",
"      Kappetein AP, Feldman TE, Mack MJ, et al. Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J 2011; 32:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/34\">",
"      Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013; 381:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/35\">",
"      Abdelaal E, Rao SV, Gilchrist IC, et al. Same-day discharge compared with overnight hospitalization after uncomplicated percutaneous coronary intervention: a systematic review and meta-analysis. JACC Cardiovasc Interv 2013; 6:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/36\">",
"      Jacobs AK, Normand SL, Massaro JM, et al. Nonemergency PCI at Hospitals with or without On-Site Cardiac Surgery. N Engl J Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/37\">",
"      Collet JP, Cuisset T, Rang&eacute; G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/38\">",
"      Sabate M, Cequier A, I&ntilde;iguez A, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 2012; 380:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/39\">",
"      R&auml;ber L, Kelb&aelig;k H, Ostojic M, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 2012; 308:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/40\">",
"      Dorman MJ, Kurlansky PA, Traad EA, et al. Bilateral internal mammary artery grafting enhances survival in diabetic patients: a 30-year follow-up of propensity score-matched cohorts. Circulation 2012; 126:2935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/41\">",
"      Puskas JD, Sadiq A, Vassiliades TA, et al. Bilateral internal thoracic artery grafting is associated with significantly improved long-term survival, even among diabetic patients. Ann Thorac Surg 2012; 94:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/42\">",
"      Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012; 367:2375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/43\">",
"      Byrne RA, Neumann FJ, Mehilli J, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet 2013; 381:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/44\">",
"      M&eacute;rie C, K&oslash;ber L, Skov Olsen P, et al. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA 2012; 308:2118.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Pradaxa (dabigatran etexilate mesylate) should not be used in patients with mechanical prosthetic heart valves file://www.fda.gov/Drugs/DrugSafety/ucm332912.htm (Accessed on December 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/46\">",
"      Van de Werf F, Brueckmann M, Connolly SJ, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J 2012; 163:931.",
"     </a>",
"    </li>",
"    <li>",
"     Pradaxa (dabigatran etexilate) US prescribing information file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9 (Accessed on November 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/48\">",
"      Palmer SC, Di Micco L, Razavian M, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev 2013; 2:CD008834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/19/21817/abstract/49\">",
"      Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381:1107.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8353 Version 2390.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-3A7D25EF8E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_19_21817=[""].join("\n");
var outline_f21_19_21817=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      ARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Pacemaker insertion for asymptomatic Mobitz type I second degree AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Azithromycin and torsades de pointes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Safety of competitive athletic participation in patients with LQTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Oxycodone toxicity and QTc prolongation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Efficacy of radiofrequency catheter ablation for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Apixaban for prevention of embolic events in atrial fibrilllation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bleeding rates with warfarin and dabigatran in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Radiofrequency catheter ablation as primary therapy for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Optimal programming for primary prevention ICDs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CORONARY ARTERY BYPASS GRAFT SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Off&ndash; compared to on-pump CABG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CORONARY HEART DISEASE, ACUTE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Time to first cardiac rehabilitation visit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Blood transfusion thresholds for acute upper GI bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CORONARY HEART DISEASE, STABLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cardiotoxicity in women with breast cancer after radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Duration of beta blocker after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      New stable ischemic heart disease guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      HEART FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Erythropoiesis stimulating agents in heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Ultrafiltration in acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      LIPID DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      CETP inhibition in patients at high risk for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Monoclonal antibody to PCSK9 in patients with drug-resistant hypercholesterolemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      MYOPERICARDIAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Pericardiectomy for recurrent pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PREVENTIVE CARDIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Aspirin for the primary prevention of cardiovascular disease and cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      REVASCULARIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Five year results of the SYNTAX trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Same-day discharge after uncomplicated PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      PCI without on-site cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Platelet monitoring to adjust antiplatelet therapy at PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Selection of stent type in acute STEMI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Bilateral internal thoracic artery grafting in patients with diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Stenting versus CABG in patients with diabetes and multivessel coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Drug-coated balloon angioplasty for restenosis following drug-eluting stent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      VALVULAR HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Early anticoagulation after implantation of a bioprosthetic aortic valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Avoid dabigatran with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      OTHER CARDIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Antiplatelet therapy in patients with CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Triple oral antithrombotic therapy for cardiovascular comorbidities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8353\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8353|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/47/40702\" title=\"table 1\">",
"      Aspirin for CVD and cancer prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=related_link\">",
"      Antithrombotic therapy in patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23529?source=related_link\">",
"      Aspirin in the primary prevention of cardiovascular disease and cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=related_link\">",
"      Azithromycin, clarithromycin, and telithromycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31576?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=related_link\">",
"      Components of cardiac rehabilitation and exercise prescription",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=related_link\">",
"      Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=related_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24889?source=related_link\">",
"      General principles of the use of intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39978?source=related_link\">",
"      HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1705?source=related_link\">",
"      Impact of anemia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=related_link\">",
"      Intracoronary stent restenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=related_link\">",
"      Nonresponse and resistance to clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37031?source=related_link\">",
"      Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=related_link\">",
"      Opioid intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=related_link\">",
"      Overview of the care of patients with stable ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=related_link\">",
"      Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31721?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=related_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11177?source=related_link\">",
"      Recurrent pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=related_link\">",
"      Risk of sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18087?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type I (Wenckebach block)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34698?source=related_link\">",
"      Treatment of acute decompensated heart failure: Components of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/5/10329?source=related_link\">",
"      Treatment of drug-resistant hypercholesterolemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13818?source=related_link\">",
"      Triple antithrombotic therapy in patients with cardiovascular disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_19_21818="Allergic contact dermatitis face";
var content_f21_19_21818=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67215%7EDERM%2F82705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67215%7EDERM%2F82705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Allergic contact dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An intense inflammatory eruption is present on the face.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Allergic contact dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inflammatory, weeping plaques are present on the face.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_19_21818=[""].join("\n");
var outline_f21_19_21818=null;
var title_f21_19_21819="Common fears in childhood and adolescence";
var content_f21_19_21819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common fears in childhood and adolescence",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age, years",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common fears",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Separation, falling, animals/insects, toilet training, bath",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        Separation, noises, toilet training, bath, bedtime",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Animals/insects, bedtime, monsters/ghosts, getting lost",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        Animals/insects, monsters/ghosts, divorce, getting lost, loss of parent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        Separation, noises, falling, bedtime",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        Social rejection, war, new situations, adoption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        Falling, burglars",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        Adoption, burglars, injections, sexual relations",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Schachter, R. When Your Child is Afraid. Simon and Schuster 1989.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_19_21819=[""].join("\n");
var outline_f21_19_21819=null;
var title_f21_19_21820="Drugs and thyroid function";
var content_f21_19_21820=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F50439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F50439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs that cause hypothyroidism, hyperthyroidism, or changes in thyroid function tests",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drugs causing hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhibition of thyroid hormone synthesis and/or release - thionamides, lithium, perchlorate, aminoglutethimide, thalidomide, and iodine and iodine-containing drugs including amiodarone, radiographic agents, expectorants (Organidin, Combid), kelp tablets, potassium iodine solutions (SSKI), Betadine douches, topical antiseptics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased absorption of T4 - cholestyramine, colestipol, colesevelam, aluminum hydroxide, calcium carbonate, sucralfate, iron sulfate, raloxifene, omeprazole, lansoprazole, and possibly other medications that impair acid secretion, sevelemer, lanthanum carbonate, and chromium; malabsorption syndromes can also diminish T4 absorption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunedysregulation - interferon-alfa, interleukin-2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suppression of TSH - dopamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Possible destructive thyroiditis - sunitinib",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased type 3 deiodination - sorafenib&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased T4 clearance and suppression of TSH - bexarotene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drugs causing hyperthyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stimulation of thyroid hormone synthesis and/or release - iodine, amiodarone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunedysregulation - interferon-alfa, interleukin-2, denileukin diftitox, ipilimumab, alemtuzumab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drugs causing abnormal thyroid function tests without thyroid dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low serum TBG - androgens, danazol, glucocorticoids, slow-release niacin (nicotinic acid), l-asparaginase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High serum TBG - estrogens, tamoxifen, raloxifene, methadone, 5-fluouracil, clofibrate, heroin, mitotane",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased T4 binding to TBG - salicylates, salsalate, furosemide, heparin (via free fatty acids), certain NSAIDs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased T4 clearance - phenytoin, carbamazepine, rifampin, phenobarbital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suppression of TSH secretion - dobutamine, glucocorticoids, octreotide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impaired conversion of T4 to T3 - amiodarone, glucocorticoids, contrast agents for oral cholecystography (eg, iopanoic acid), propylthiouracil, propanolol, nadolol",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_19_21820=[""].join("\n");
var outline_f21_19_21820=null;
var title_f21_19_21821="Probability of pregnancy by day of intercourse";
var content_f21_19_21821=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Possibility of pregnancy from intercourse on days relative to ovulation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 426px; height: 255px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Wilcox A, et al. Post-ovulatory aging of the human oocyte and embryo failure. Hum Reprod 1998; 12:394. Reproduced with permission from the Institute for Reproductive Health, Georgetown University.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_19_21821=[""].join("\n");
var outline_f21_19_21821=null;
var title_f21_19_21822="Treatment of patients with carcinoma of unknown primary";
var content_f21_19_21822=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F86664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F86664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Treatment of patients with carcinoma of unknown primary",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 388px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Greco FA and Hainsworth JD. Cancer of Unknown Primary Site. In: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology, 9th Edition, DeVita VT, Lawrence TS, Rosenberg SA, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_19_21822=[""].join("\n");
var outline_f21_19_21822=null;
var title_f21_19_21823="Contents: Adrenal disease";
var content_f21_19_21823=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/56/1934\">",
"       Endocrinology and Diabetes",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Adrenal disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Adrenal disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Adrenal androgens",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/8/40071\">",
"           Adrenal hyperandrogenism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/60/21445\">",
"           Measurement of adrenal androgens",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/1/9240\">",
"           Metabolism of adrenal steroids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/62/21481\">",
"           Premature adrenarche",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Adrenal insufficiency",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/0/40969\">",
"           Causes of primary adrenal insufficiency (Addison's disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/50/3880\">",
"           Causes of secondary and tertiary adrenal insufficiency in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/0/33800\">",
"           Clinical manifestations of adrenal insufficiency in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/46/44777\">",
"           Diagnosis of adrenal insufficiency in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/20/24905\">",
"           Evaluation of the response to ACTH in adrenal insufficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/17/25876\">",
"           Hyponatremia and hyperkalemia in adrenal insufficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/20/21830\">",
"           Insulin-induced hypoglycemia test",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/19/40246\">",
"           Measurement of ACTH, CRH, and other hypothalamic and pituitary peptides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/48/16135\">",
"           Metyrapone stimulation tests",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/42/9896\">",
"           Pathogenesis of autoimmune adrenal insufficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/50/22312\">",
"           Pituitary and adrenal gland dysfunction in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/31/38388\">",
"           Thyroid gland dysfunction in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/47/42745\">",
"           Treatment of adrenal insufficiency in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/7/12408\">",
"           Unusual causes of adrenal insufficiency",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Adrenal tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/33/12826\">",
"           Clinical presentation and evaluation of adrenocortical tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/43/26295\">",
"           Pharmacology and toxicity of adrenal enzyme inhibitors and adrenolytic agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/8/18569\">",
"           The adrenal incidentaloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/37/34390\">",
"           Treatment of adrenocortical adenomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/51/40762\">",
"           Treatment of adrenocortical carcinoma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Anatomy and physiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/46/28391\">",
"           Adrenal steroid biosynthesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/35/7736\">",
"           Assays of the renin-angiotensin-aldosterone system in adrenal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/3/16435\">",
"           Basic principles in the laboratory evaluation of adrenocortical function",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/20/2376\">",
"           Chapter 6C: Aldosterone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/16/263\">",
"           Dehydroepiandrosterone and its sulfate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/40/31367\">",
"           Glucocorticoid effects on the nervous system and behavior",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/19/40246\">",
"           Measurement of ACTH, CRH, and other hypothalamic and pituitary peptides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/48/23302\">",
"           Normal adrenarche",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/44/6857\">",
"           Physiology of corticotropin-releasing hormone",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Congenital adrenal hyperplasia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/46/28391\">",
"           Adrenal steroid biosynthesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/32/15878\">",
"           Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/21/1367\">",
"           Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/9/24726\">",
"           Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/49/11034\">",
"           Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/6/19560\">",
"           Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/62/21481\">",
"           Premature adrenarche",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/16/7433\">",
"           Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/51/35641\">",
"           Uncommon causes of congenital adrenal hyperplasia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cushing's syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/55/26489\">",
"           Causes and pathophysiology of Cushing's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/44/26311\">",
"           Corticotropin-releasing hormone stimulation test",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/45/730\">",
"           Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/35/22072\">",
"           Cushing's syndrome due to primary pigmented nodular adrenocortical disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/39/4725\">",
"           Cushing's syndrome in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/41/37528\">",
"           Dexamethasone suppression tests",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/48/22282\">",
"           Epidemiology and clinical manifestations of Cushing's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/31/31225\">",
"           Establishing the cause of Cushing's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/25/21913\">",
"           Establishing the diagnosis of Cushing's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/19/40246\">",
"           Measurement of ACTH, CRH, and other hypothalamic and pituitary peptides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/8/132\">",
"           Measurement of cortisol in serum and saliva",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/22/41319\">",
"           Measurement of urinary excretion of endogenous and exogenous glucocorticoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/0/3081\">",
"           Medical therapy of hypercortisolism (Cushing���������s syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/48/16135\">",
"           Metyrapone stimulation tests",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/63/1016\">",
"           Overview of the treatment of Cushing's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/2/19496\">",
"           Persistent or recurrent Cushing���������s disease: Surgical adrenalectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/26/17834\">",
"           Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/29/36312\">",
"           Vasopressin and desmopressin stimulation test",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Glucocorticoid therapy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/61/31703\">",
"           Determinants of glucocorticoid dosing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/37/28249\">",
"           Glucocorticoid effects on the immune system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/37/22103\">",
"           Glucocorticoid withdrawal",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/60/7114\">",
"           Major side effects of inhaled glucocorticoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/47/27386\">",
"           Major side effects of systemic glucocorticoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/42/23208\">",
"           Pharmacologic use of glucocorticoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/62/17384\">",
"           The surgical patient taking glucocorticoids",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hyperaldosteronism",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/56/40838\">",
"           Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/13/5338\">",
"           Approach to the patient with hypertension and hypokalemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/35/7736\">",
"           Assays of the renin-angiotensin-aldosterone system in adrenal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/1/37911\">",
"           Clinical features of primary aldosteronism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/5/22615\">",
"           Familial hyperaldosteronism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/16/40199\">",
"           Treatment of primary aldosteronism",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypoaldosteronism",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/35/7736\">",
"           Assays of the renin-angiotensin-aldosterone system in adrenal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/44/9930\">",
"           Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/50/22312\">",
"           Pituitary and adrenal gland dysfunction in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/31/38388\">",
"           Thyroid gland dysfunction in HIV-infected patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/53/16211\">",
"           Cortisol metabolism in chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/49/17174\">",
"           Multiple endocrine neoplasia type 1: Definition and genetics",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pheochromocytoma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/14/23786\">",
"           Clinical presentation and diagnosis of pheochromocytoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/54/21351\">",
"           Pheochromocytoma in genetic disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/54/32616\">",
"           Treatment of pheochromocytoma in adults",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-F368A81FC4-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f21_19_21823=[""].join("\n");
var outline_f21_19_21823=null;
